Professor Syed Hussain

MBBS, MSc, MD, FRCP

Clinical Medicine, School of Medicine and Population Health

Professor of Medical Oncology

syed.hussain@sheffield.ac.uk
+44 114 215 9682

Room 228, 2nd Floor, Broomcross Building, Weston Park Hospital

Full contact details

Professor Syed Hussain
Clinical Medicine, School of Medicine and Population Health
Room 228, 2nd Floor, Broomcross Building
Weston Park Hospital
Whitham Road
Sheffield
S10 2SJ

Profile

For enquiries please contact - ClinMed-Operational@sheffield.ac.uk

Professor Hussain graduated from Dow Medical College Karachi in 1994. He completed his general medical professional training in UK. He did his Doctorate in Oncology from University of Birmingham. He completed his medical oncology training in Birmingham, United Kingdom and received his certification and specialist registration in medical oncology.

Professor Hussain is Professor and Honorary Consultant in Medical Oncology at the University of Sheffield and Sheffield Teaching Hospitals NHS Trust. His major areas of interest are management of urological cancers, clinical trials, early drug development and translational medicine. He has set up several clinical trials from early phase to late phase studies during his career. His work on organ preservation in bladder cancer moved all the way from an early phase I study (Hussain et al Annals of Oncology 2001) to phase II efficacy study (Hussain et al BJC 2004) that led to a Cancer Research UK funded study BC2001 trial that was reported in New England Journal of Medicine (James, Hussain, Hall et al April 2012). This study has now changed the standard of care for patients with muscle invasive bladder cancer opting for organ preservation treatment globally. He has tailored split dose cisplatin regimen that has led to expand the spectrum of patients receiving cisplatin-based chemotherapy in bladder cancer (Hussain et al BJC 2004). He is a principal investigator of several studies in urological cancers. He was chief investigator of a national randomised placebo-controlled phase II neo-adjuvant study (NEOBLADE) in muscle invasive bladder cancer. He has served as a chief investigator of various early phase clinical trials, and translational studies. He is a chief investigator of a first in human window of opportunity study (INVEST) investigating the role of intravesical/intratumoral atezolizumab in patients with bladder cancer undergoing curative cystectomy. This is sponsored by STH and funded by Roche. He is also chief investigator of an international window of opportunity trial SOGUG NEOWIN investigating the role of erdafitinib and cetrelimab in FGF mutant bladder cancer patients undergoing curative cystectomy. This is jointly led by Hussain (UK), with Andrea Necchi (Italy), Yohann Loriot (France) and Guillermo Velasco (Spain) as other co-chief investigators. This study is funded by Janssen. He has authored over 125 peer-reviewed publications including 4 book chapters in textbooks of oncology. His Google scholar H-index is 40 with over 9800 citations (April 2023). He has published in high impact journals including New England Journal of Medicine, Lancet, Lancet Oncology, JAMA, JAMA Oncology, Journal of Clinical Oncology, European Urology, Annals of Oncology, Nature Communications, Clinical Cancer Research, British Journal of Cancer. He has been an invited speaker to number of national and international meetings and have delivered over 110 invited lectures. He has secured funding from cancer charities, national funding bodies and industries of over £15 million.

Professor Hussain was the member of NCRI Bladder and Renal group and Chair of the NCRI- Advanced Bladder Cancer sub-group in his national role. Professor Hussain was the expert witness to NICE on successful technology appraisals of Atezolizumab (2017), Avelumab (2021) and Nivolumab in Bladder cancer (2022).

Research interests

My major areas of interest are management of urological cancers, clinical trials, early drug development and translational medicine. I have set up a large number of clinical trials from early phase to late phase studies during my career.

My work on organ preservation in bladder cancer moved all the way from an early phase I study (Hussain et al Annals of Oncology 2001), to phase II efficacy study (Hussain et al BJC 2004) that led to a Cancer Research UK funded study BC2001 trial that was reported in New England Journal of Medicine (James, Hussain, Hall et al April 2012).

This study has now changed the standard of care for patients with muscle invasive bladder cancer opting for organ preservation treatment. I am principal investigator of a number of studies in urological cancers.

I am chief investigator of a national randomised placebo-controlled phase II neo-adjuvant study in muscle invasive bladder cancer and have served as chief investigator of various early phase trials, and translational studies.

I have authored over 125 peer-reviewed publications including 4 book chapters in textbooks of oncology. My Google scholar H-index is 40 with over 9800 citations (April 2023). I have published in high impact journals including New England Journal of Medicine, Lancet, Lancet Oncology, JAMA, JAMA Oncology, Journal of Clinical Oncology, European Urology, Annals of Oncology, Nature Communications, Clinical Cancer Research, British Journal of Cancer. I have been an invited speaker at a number of national and international meetings and have delivered over 110 invited lectures. I have secured funding from cancer charities, national funding bodies and industries of over £15 million.

Current Projects

Setting up of clinical trials in bladder cancers.
Early phase studies in bladder cancer.
Development of panel of Biomarkers in bladder cancer.
Translational research linked to bladder cancer clinical trials.

Publications

Show: Featured publications All publications

Featured publications

This person does not have any publications available.

All publications

Journal articles

Conroy S, Jubber I, Noon AP, Rosario DJ, Griffin J, Morgan S, Hubbard R, Kennish S, Mitchell S, Venugopal S , Linton K et al (2024) Real-word outcomes for high-risk non-muscle-invasive bladder cancer: screened patients for the BRAVO trial. BJU International. View this article in WRRO
Loriot Y, Necchi A, Hussain SA & De Velasco Oria GA (2024) 2020TiP SOGUG-NEOWIN: A phase II, open-label, multi-centre trial evaluating the efficacy and safety of erdafitinib (ERDA) monotherapy and ERDA and cetrelimab (CET) as neoadjuvant treatment in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC) and FGFR gene alterations. Annals of Oncology, 35, S1163-S1164.
Azam F, Alharbi H, Alshangiti A, Zar Gul AR, Bukhari N, Ouda M, Anwar Hussain S & Ibnshamsah F (2024) Eligibility Criteria for Different Platinum-Based Chemotherapy Regimens in Metastatic Urothelial Carcinoma. Cureus, 16(8), e66520.
Jackson-Spence F, Ackerman C, Jones R, Toms C, Jovaisaite A, Young M, Hussain S, Protheroe A, Birtle A, Chakraborti P , Huddart R et al (2024) Biomarkers associated with survival in patients with platinum-refractory urothelial carcinoma treated with paclitaxel. Urologic Oncology: Seminars and Original Investigations.
Crabb SJ, Hussain SA, Oughton JB, Swain J, Cairns DA, Collinson M, Ainsworth G, McCready D, Griffin J, Heath P , Quayle L et al (2024) Use of gene expression patterns to identify unique molecular subtypes in muscle invasive bladder cancer: GUSTO.. Journal of Clinical Oncology, 42(16_suppl), TPS4621-TPS4621.
Hussain SA, Loriot Y, de Velasco G & Necchi A (2024) SOGUG-NEOWIN: A phase 2, open-label, multi-centre, multi-national interventional trial evaluating the efficacy and safety of erdafitinib (ERDA) monotherapy and ERDA and cetrelimab (CET) as neoadjuvant treatment in patients with cisplatin-ineligible muscle-invasive bladder cancer (MIBC) whose tumours express FGFR gene alterations.. Journal of Clinical Oncology, 42(16_suppl), TPS4623-TPS4623.
Naqvi SAA, Saxena A, Faisal KS, Bibi A, Khan MA, Cobran EK, Hussain SA, Riaz IB, Bryce AH & Singh P (2024) Stratified absolute benefit with adjuvant immunotherapy (aIO) in muscle-invasive bladder cancer (MIBC): A meta-analysis.. Journal of Clinical Oncology, 42(16_suppl), e16619-e16619.
Faisal KS, Raina A, Khakwani KZR, Bin Riaz Z, Shah VS, Cobran EK, Singh P, Hussain SA, Bryce AH & Bin Riaz I (2024) Cost-effectiveness analysis of contemporary first-line (1L) agents in locally advanced/metastatic urothelial carcinoma (la/mUC).. Journal of Clinical Oncology, 42(16_suppl), 4591-4591.
Catto JWF, Hussain SA, Tran B, Pignot G, Master V, Rouprêt M, Tubaro A, Shimizu N, Vasdev N, Nishiyama H , Daneshmand S et al (2024) UPDATED EFFICACY AND SAFETY OF ORAL ERDAFITINIB IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN–UNRESPONSIVE, HIGH-RISK NON-MUSCLE–INVASIVE BLADDER CANCER WITH FGFR3/2 ALTERATIONS IN THOR-2 COHORT 2. Urologic Oncology: Seminars and Original Investigations, 42, S53-S53.
Daneshmand S, Zaucha R, Vasdev N, Gartrell BA, Lotan Y, Hussain SA, Lee EK, Procopio G, Galanternik F, Pignot G , Sundi D et al (2024) MARKER LESION STUDY OF ORAL ERDAFITINIB IN PATIENTS WITH INTERMEDIATE-RISK NON-MUSCLE–INVASIVE BLADDER CANCER WITH FGFR3/2 ALTERATIONS IN THOR-2: UPDATED COHORT 3 RESULTS. Urologic Oncology: Seminars and Original Investigations, 42, S58-S58.
Necchi A, Hussain SA, Loriot Y & de Velasco G (2024) SOGUG-NEOWIN: A Phase 2, open-label, multi-centre, multi-national interventional trial evaluating the efficacy and safety of Erdafitinib (ERDA) monotherapy and ERDA and Cetrelimab (CET) as neoadjuvant treatment in cisplatin-ineligible patients with Muscle-Invasive Bladder Cancer (MIBC) whose tumours express FGFR gene alterations. European Urology, 85, S427-S427.
Smith TAD, West CML, Joseph N, Lane B, Irlam-Jones J, More E, Mistry H, Reeves KJ, Song YP, Reardon M , Hoskin PJ et al (2024) A hypoxia biomarker does not predict benefit from giving chemotherapy with radiotherapy in the BC2001 randomised controlled trial. eBioMedicine, 101, 105032-105032.
Rehan A, Qureshi M, Goktas Aydin S, O'Connor K, Serra M, Charnley N, Muazzam I, Bansal V, Vasudev N, Coe F , Kagzi MM et al (2024) Real world outcomes for maintenance avelumab treatment in locally advanced/metastatic urothelial cancer after platinum-based chemotherapy.. Journal of Clinical Oncology, 42(4_suppl), 584-584.
Hussain SA, Oughton JB, Smith Whelan R, Green A, Hubbard R, Kennish S, Senior E, Kendall J, McCready D, Collinson FJ , Griffin J et al (2024) INVEST: A phase Ib window of opportunity study of atezolizumab administered either intravesically or direct tumour injection in patients with bladder cancer prior to radical cystectomy.. Journal of Clinical Oncology, 42(4_suppl), tps710-tps710.
Qureshi M, Rehan A, Mok WK, Salawu A, Goktas Aydin S, Tay J, Hubbard R, Catto JWF & Hussain SA (2024) Thromboembolic events associated with neoadjuvant chemotherapy for muscle invasive cancer of the bladder.. Journal of Clinical Oncology, 42(4_suppl), 586-586.
Griffin J, Down J, Quayle LA, Heath PR, Gibb EA, Davicioni E, Liu Y, Zhao X, Swain J, Wang D , Hussain S et al (2024) Verification of molecular subtyping of bladder cancer in the GUSTO clinical trial. The Journal of Pathology: Clinical Research, 10(2). View this article in WRRO
Catto JWF, Tran B, Rouprêt M, Gschwend JE, Loriot Y, Nishiyama H, Redorta JP, Daneshmand S, Hussain SA, Cutuli HJ , Procopio G et al (2024) Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer. Annals of Oncology, 35(1), 98-106.
Szabados BE, Nogueron Martinez E, Alvarez Marquez FJ, Castellano Gauna DE, Rodriguez-Vida A, Garcias de Espana MC, Hussain SA, Alvarez Fernandez C, Linch M, Bonfill Abella T , Gross Goupil M et al (2023) 2363MO A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in non-urothelial, muscle invasive bladder cancer (ABACUS-2). Annals of Oncology, 34, S1201-S1202.
Catto JWF, Tran B, Roupret M, Gschwend JE, Loriot Y, Nishiyama H, Palou J, Daneshmand S, Hussain SA, Cutuli HJ , Procopio G et al (2023) LBA102 THOR-2 cohort 1: Results of erdafitinib (ERDA) vs intravesical chemotherapy (chemo) in patients (pts) with high-risk non–muscle-invasive bladder cancer (HR NMIBC) with select fibroblast growth factor receptor alterations (FGFRALT) who received prior bacillus calmette-guérin (BCG) treatment. Annals of Oncology, 34, S1341-S1342.
Jackson-Spence F, Marin AP, Puente J, Molina-Cerrillo J, Hussain SA, Ackerman C, Bonsu N, Kelly J, Loriot Y, Powles TB & Pulido EG (2023) 2408TiP DISCUS: A randomised phase II study of 3 vs 6 cycles of chemotherapy followed by maintenance avelumab in advanced urothelial cancer - Wearable devices and circulating biomarkers assessing quality of life and surrogate efficacy endpoints. Annals of Oncology, 34, S1224-S1225.
Naqvi SAA, Riaz IB, He H, Imran M, Orme J, Childs DS, Ravi P, Hussain SA, Singh P & Bryce AH (2023) The role of volume of disease for treatment selection in patients with metastatic castration sensitive prostate cancer (mCSPC): A living meta-analysis.. Journal of Clinical Oncology, 41(16_suppl), 5088-5088.
Meeks JJ, Black PC, Galsky M, Grivas P, Hahn NM, Hussain SA, Milowsky MI, Steinberg GD, Svatek RS & Rosenberg JE (2023) Checkpoint Inhibitors in Urothelial Carcinoma—Future Directions and Biomarker Selection. European Urology.
Iyer G, Siefker-Radtke A, Milowsky M, Shore N, Gao X, Reimers MA, Hahn N, Cosman R, Matsubara N, Necchi A , Robbrecht D et al (2023) Abstract CT119: A first-in-human phase 1 study of LOXO-435, a potent, highly isoform-selective FGFR3 inhibitor in advanced solid tumors with FGFR3 alterations (trial in progress). Cancer Research, 83(8_Supplement), CT119-CT119.
Khetrapal P, Catto J, Ambler G, Williams N, Al-Hammouri T, Khan MS, Thurairaja R, Nair R, Nathan S, Sridhar A , Ahmad I et al (2023) PD36-12 MEASURING OBJECTIVE RECOVERY OF ACTIVITY LEVELS USING WEARABLE DEVICES FOLLOWING OPEN VS INTRACORPOREAL ROBOTIC CYSTECTOMY: SECONDARY OUTCOMES ANALYSIS OF THE IROC RANDOMIZED TRIAL. Journal of Urology, 209(Supplement 4).
Ayaz A, Naqvi SAA, Tripathi N, Ijaz H, Mir SA, Singh P, Hussain SA, Sonpavde GP, McGregor BA, Bryce AH , Riaz IB et al (2023) Pathologic response with neoadjuvant chemotherapy, immunotherapy, and chemo-immunotherapy for muscle-invasive bladder cancer (MIBC): A systematic review and meta-analysis.. Journal of Clinical Oncology, 41(6_suppl), 531-531.
Riaz IB, Naqvi SAA, He H, Siddiqi R, Asghar N, Ravi P, Hussain SA, Singh P & Bryce AH (2023) A living interactive systematic review and network meta-analysis evaluating systemic therapies in metastatic castration-sensitive prostate cancer (mCSPC).. Journal of Clinical Oncology, 41(6_suppl), 193-193.
Daneshmand S, Zaucha R, Gartrell BA, Lotan Y, Hussain SA, Lee EK, Procopio G, Galanternik F, Naini V, Carcione J , Triantos S et al (2023) Phase 2 study of the efficacy and safety of erdafitinib in patients (pts) with intermediate-risk non–muscle-invasive bladder cancer (IR-NMIBC) with FGFR3/2 alterations (alt) in THOR-2: Cohort 3 interim analysis.. Journal of Clinical Oncology, 41(6_suppl), 504-504.
Khetrapal P, Catto JWF, Ambler G, Williams NR, Al-Hammouri T, Khan MS, Thurairaja R, Nair R, Nathan S, Sridhar A , Ahmed I et al (2023) Comparing objective recovery of activity levels using wearable devices in open vs. intracorporeal robotic cystectomy: An analysis of the secondary outcomes of the iROC randomized trial. European Urology, 83, S219-S220.
Catto JWF, Mandrik O, Quayle LA, Hussain SA, McGrath J, Cresswell J, Birtle AJ, Jones RJ, Mariappan P, Makaroff LE , Knight A et al (2023) Diagnosis, treatment and survival from bladder, upper urinary tract and urethral cancers: Real world findings from NHS England between 2013 and 2019. BJU International.
van der Heijden MS, Powles T, Petrylak D, de Wit R, Necchi A, Sternberg CN, Matsubara N, Nishiyama H, Castellano D, Hussain SA , Bamias A et al (2023) Re: Predictive Biomarkers for Survival Benefit With Ramucirumab in Urothelial Cancer in the RANGE Trial Editorial Comment. JOURNAL OF UROLOGY, 209(1), 291-291.
Crabb SJ, Hussain S, Soulis E, Hinsley S, Dempsey L, Trevethan A, Song Y, Barber J, Frew J, Gale J , Faust G et al (2023) A randomized, double-blind, biomarker-selected, phase II clinical trial of maintenance poly ADP-ribose polymerase inhibition with rucaparib following chemotherapy for metastatic urothelial carcinoma. Journal of Clinical Oncology, 41(1), 54-64.
Conroy S, Pang K, Jubber I, Hussain SA, Rosario DJ, Cumberbatch MG, Catto JWF & Noon AP (2022) Hyperthermic intravesical chemotherapy with mitomycin‐C for the treatment of high‐risk non‐muscle‐invasive bladder cancer patients. BJUI Compass. View this article in WRRO
Crabb SJ, Dempsey L, Soulis E, Hinsley S, Song YP, Barber J, Frew J, Gale J, Faust G, Brock S , McGovern UB et al (2022) 1772P Characterisation of a DNA repair deficiency (DRD) biomarker phenotype in metastatic urothelial carcinoma (mUC) within the ATLANTIS clinical trial platform. Annals of Oncology, 33, S1348-S1348.
Riaz IB, Naqvi SAA, He H, Asghar N, Siddiqi R, Khakwani KZR, Liu H, Hussain SA, Singh P, Murad M & Bryce AH (2022) 1417P Mixed treatment comparisons evaluating contemporary therapies in metastatic castration sensitive prostate cancer (mCSPC): A living systematic review. Annals of Oncology, 33, S1193-S1193.
Smith TAD, West CM, Lane B, Irlam-Jones J, More E, Mistry H, Hoskin PJ, Hussain SA, Hall E, Porta N , Huddart RA et al (2022) 1734MO Hypoxic bladder cancers have a poorer outcome following hypofractionated vs conventionally fractionated radiotherapy in the BC2001 and BCON randomised trials. Annals of Oncology, 33, S1330-S1330.
Jones RJ, Hussain SA, Birtle AJ, Song YP, Enting D, Faust G, Hilman S, Jagdev S, McGovern UB, Parikh O , Lewis A et al (2022) A randomised, double blind, phase II clinical trial of maintenance cabozantinib following chemotherapy for metastatic urothelial carcinoma (mUC): Final analysis of the ATLANTIS cabozantinib comparison.. Journal of Clinical Oncology, 40(17_suppl), lba4505-lba4505.
Ferm S, Zheng K, Cheng ZA, Tsistrakis S, Nadella D, Gemei A, Fisher C, Hussain S & Kim SH (2022) COMPARISON BETWEEN A NOVEL 0.025-INCH AND STANDARD 0.035-INCH GUIDEWIRE IN WIRE- GUIDED ERCP CANNULATION: INTERIM RESULTS OF A PROSPECTIVE, RANDOMIZED TRIAL. Gastrointestinal Endoscopy, 95(6), AB287-AB287.
Ikram W, Naqvi SAA, Raina A, Fatima E, Siddiqi R, Islam M, Asghar N, Khakwani KZR, Khan AM, Hussain SA , Bryce AH et al (2022) Quantifying the absolute benefit of neoadjuvant chemotherapy followed by definitive therapy in patients with muscle-invasive bladder cancer: A systematic review and meta-analysis.. Journal of Clinical Oncology, 40(16_suppl), 4594-4594.
Conroy S, Hubbard R, Noon AP, Hussain SA, Griffin J, Kennish S & Catto JWF (2022) Case of the month from the University of Sheffield, UK : expediting definitive treatment in patients with invasive bladder cancer : an MRI-guided pathway. BJU International, 129(6), 691-694. View this article in WRRO
Catto JWF, Khetrapal P, Ricciardi F, Ambler G, Williams NR, Al-Hammouri T, Khan MS, Thurairaja R, Nair R, Feber A , Dixon S et al (2022) Effect of robot-assisted radical cystectomy with intracorporeal urinary diversion vs open radical cystectomy on 90-day morbidity and mortality among patients with bladder cancer : a randomized clinical trial. JAMA. View this article in WRRO
Riaz IB, Islam M, Khan AM, Naqvi SAA, Siddiqi R, Khakwani KZR, Asghar N, Ikram W, Hussain SA, Singh P , Warner JL et al (2022) Disparities in Representation of Women, Older Adults and Racial/Ethnic Minorities in Immune Checkpoint Inhibitor Trials.. Am J Med.
Shimizu N, Hussain SA, Obara W, Yamasaki T, Takashima S, Hasegawa T, Iguchi M, Igarashi K, Ogawa O & Fujioka T (2022) A Phase 2 Study of S-588410 Maintenance Monotherapy for Platinum-Treated Advanced or Metastatic Urothelial Carcinoma. Bladder Cancer, 1-14.
Hussain SA, Lester JF, Jackson R, Gornall M, Qureshi M, Elliott A, Crabb SJ, Huddart RA, Vasudev N, Birtle AJ , Worlding J et al (2022) Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE) : a double-blind, randomised, phase 2 trial. The Lancet Oncology, 23(5), 650-658.
van der Heijden MS, Powles T, Petrylak D, de Wit R, Necchi A, Sternberg CN, Matsubara N, Nishiyama H, Castellano D, Hussain SA , Bamias A et al (2022) Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial. Nature Communications, 13.
Vogelzang NJ, Beer TM, Gerritsen W, Oudard S, Wiechno P, Kukielka-Budny B, Samal V, Hajek J, Feyerabend S, Khoo V , Stenzl A et al (2022) Efficacy and Safety of Autologous Dendritic Cell–Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer. JAMA Oncology, 8(4), 546-546.
Riaz IB, Islam M, Ikram W, Naqvi SAA, Maqsood H, Saleem Y, Riaz A, Ravi P, Hussain SA, Warner JL , Odedina F et al (2022) A quantitative synthesis of disparities in the inclusion of racial/ethnic minorities and older adults in prostate cancer clinical trials over the last three decades.. Journal of Clinical Oncology, 40(6_suppl), 26-26.
Ikram W, Naqvi SAA, Fatima E, Siddiqi R, Islam M, Asghar N, Khakwani KZR, Khan AM, Xu W, Hussain SA , Sonpavde GP et al (2022) A systematic review and network meta-analysis evaluating neoadjuvant treatments in muscle-invasive bladder cancer.. Journal of Clinical Oncology, 40(6_suppl), 518-518.
Crabb SJ, Hussain SA, Soulis E, Hinsley S, Dempsey L, Trevethan A, Song YP, Barber J, Frew JA, Gale J , Faust G et al (2022) A randomized, double blind, biomarker selected, phase II clinical trial of maintenance PARP inhibition following chemotherapy for metastatic urothelial carcinoma (mUC): Final analysis of the ATLANTIS rucaparib arm.. Journal of Clinical Oncology, 40(6_suppl), 436-436.
Riaz IB, Naqvi SAA, Ikram W, Siddiqi R, Asghar N, Khakwani KZR, Khalid A, Hussain SA, Singh P & Bryce AH (2022) First-line treatment options in metastatic castration-sensitive prostate cancer: A systematic review and network meta-analysis.. Journal of Clinical Oncology, 40(6_suppl), 132-132.
Hussain SA, Qureshi M, Tahir B, Rehan A & Catto JWF (2022) Real-world evidence from a single U.K. cancer center for atezolizumab in second-line setting in advanced urothelial cancer: Moving beyond clinical trials.. Journal of Clinical Oncology, 40(6_suppl), 461-461.
Catto JWF, Kelly JD, Khetrapal P, Ambler G, Ricciardi F, Khan S, Feber A, Dixon S, Williams N, Ahmed I , Charlesworth P et al (2022) Robot assisted radical cystectomy with intracorporeal urinary diversion versus open radical cystectomy: Results from the iROC prospective randomised controlled trial. European Urology, 81, S1125-S1125.
Hall E, Hussain SA, Porta N, Lewis R, Crundwell M, Jenkins P, Rawlings C, Tremlett J, Sreenivasan T, Wallace J , Syndikus I et al (2022) Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial. European Urology.
Ansari J, Eltigani Mohmmed Y, Ghazal-Aswad S, Ansari H, Akhter SMJ, Hassoun Hadid O, Rizwan S, Almazrouei R, Dawoud E, Azribi F , Elhasin H et al (2021) Rare case of chemotherapy-refractory metastatic vaginal squamous cell carcinoma with complete response to concurrent pembrolizumab and radiotherapy- case report and literature review. Gynecologic Oncology Reports, 38. View this article in WRRO
Baek S, Cohen J, Ferm S, Fisher C, Kim M, Wongvravit J, Hussain S & Kim SH (2021) S2563 Bacteremia From ERCP? A Rare Case of Streptococcus salivarius Bacteremia After ERCP Without Oral Lesion. The American Journal of Gastroenterology, 116(1), s1079-s1080.
Cohen J, Fisher C, Baek S, Kim M, Wongvravit J, Cheng A, Kim SH & Hussain S (2021) S2355 An Unusual Presentation of a Rare Cause of Lower Gastrointestinal Bleeding: Cecal Dieulafoy’s Lesion Presenting as Melena. The American Journal of Gastroenterology, 116(1), s1002-s1002.
Zheng K, Baek S, Hussain S & Kim SH (2021) S2372 Hemostatic Powder and Over-the-Scope Clip for Duodenal Variceal Bleeding. The American Journal of Gastroenterology, 116(1), s1008-s1008.
Ansari J, Farrag A, Ali A, Abdelgelil M, Murshid E, Alhamad A, Ali M, Ansari H, Hussain S & Glaholm J (2021) Concurrent use of nivolumab and radiotherapy for patients with metastatic non‑small cell lung cancer and renal cell carcinoma with oligometastatic disease progression on nivolumab. Molecular and Clinical Oncology, 15(4).
Mariappan P, Ahmad I, Amer T, Andersen LD, Baker S, Bhatt J, Brown M, Bryan R, Catto JWF, Chahal R , Chapman A et al (2021) The Scottish Bladder Cancer Quality Performance Indicators Influencing Outcomes, Prognosis, and Surveillance (Scot BC Quality OPS) Clinical Project. European Urology Focus.
Powles T, Csőszi T, Özgüroğlu M, Matsubara N, Géczi L, Cheng SY-S, Fradet Y, Oudard S, Vulsteke C, Morales Barrera R , Fléchon A et al (2021) Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. The Lancet Oncology, 22(7), 931-945.
Hussain SA, Porta N, Hall E, Qureshi M, Lewis R, Huddart R & James ND (2021) Reply to Santhanam Sundar and Paul Symonds' Letter to the Editor re: Syed A. Hussain, Nuria Porta, Emma Hall, et al. Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial. Eur Urol 2021;79:307-15.. Eur Urol.
Latif MF, Azam F, Tirmazy SH, Bashir S, Ibnshamsah F, Al Selwi WM, Bukhari N, Alwbari A, Alshangiti A, Gabsi A , Al-Shamsi HO et al (2021) Impact of COVID 19 pandemic on psychological wellbeing of oncology clinicians in MENA (Middle East and North Africa) region.. Journal of Clinical Oncology, 39(15_suppl), e24105-e24105.
Riaz IB, Islam M, Khan AM, Naqvi SAA, Siddiqi R, Hussain SA, Singh P, Warner JL, Sonpavde GP, Duma N & Bryce AH (2021) Disparities in reporting and representation of women, older adults and racial minorities in immune checkpoint inhibitor (ICI) clinical trials.. Journal of Clinical Oncology, 39(15_suppl), 6549-6549.
Pond GR, Agarwal A, Ornstein M, Garcia J, Gupta R, Grivas P, Drakaki A, Lee J-L, Kanesvaran R, Lorenzo GD , Verolino P et al (2021) Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors. Clinical Genitourinary Cancer.
Riaz IB, He H, Ryu AJ, Siddiqi R, Naqvi SAA, Yao Y, Husnain M, Narasimhulu DM, Mathew J, Sipra QUAR , Vandvik PO et al (2021) A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma. European Urology.
Hussain SA, Shimizu N, Obara W, Yamasaki T, Takashima S, Hasegawa T, Iguchi M, Igarashi K, Ogawa O & Fujioka T (2021) Phase II open-label study of S-588410 as maintenance monotherapy after first-line platinum-containing chemotherapy in patients with advanced or metastatic urothelial carcinoma.. Journal of Clinical Oncology, 39(6_suppl), 440-440.
Catto JWF, Downing A, Mason S, Wright P, Absolom K, Bottomley S, Hounsome L, Hussain S, Varughese M, Raw C , Kelly P et al (2021) Quality of Life After Bladder Cancer: A Cross-sectional Survey of Patient-reported Outcomes. European Urology.
Williams ST, El Badri S & Hussain SA (2021) Urological cancer patients receiving treatment during COVID-19 : a single-centre perspective. British Journal of Cancer.
Hussain SA, Porta N, Hall E, Salawu A, Lewis R, Sreenivasan T, Wallace J, Crundwell M, Jenkins P, Tremlett J , Huddart R et al (2021) Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial. European Urology, 79(2), 307-315.
Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, Ogawa O, Park SH, Lee J-L, De Giorgi U , Bögemann M et al (2020) Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. The Lancet Oncology, 21(12), 1574-1588.
Riaz IB & Hussain SA (2020) Perioperative Treatment in Muscle-invasive Bladder Cancer: Analysis of Secondary Endpoints in a Randomized Trial Comparing Gemcitabine and Cisplatin Versus Dose-dense Methotrexate, Vinblastine, Adriamycin, and Cisplatin. European Urology.
Reed O, Jubber I, Griffin J, Noon A, Goodwin L, Hussain S, Cumberbatch M & Catto J (2020) Occupational Bladder cancer: A cross section survey of previous employments, tasks and exposures matched to cancer phenotypes. PLoS ONE.
Martinez Chanza N, Werner L, Plimack E, Yu EY, Alva AS, Crabb SJ, Powles T, Rosenberg JE, Baniel J, Vaishampayan UN , Berthold DR et al (2020) Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers. European Urology Oncology, 3(5), 671-679.
Cohen J, Pakala T, Baek S, Kim M, Shah D, Hussain S, Kim SH & Gutkin E (2020) S3088 Single Center Evaluation of Patient and Healthcare System Related Factors Influencing Inadequate Bowel Preparation Rates. The American Journal of Gastroenterology, 115(1), s1628-s1628.
Cohen J, Tsistrakis S, Hussain S, Kim SH & Nussbaum M (2020) S2821 Ileocolonic Intussusception Associated Large B-Cell Lymphoma. The American Journal of Gastroenterology, 115(1), s1475-s1475.
Cohen J, Schwarzbaum D, Tsistrakis S, Kim SH & Hussain S (2020) S2339 Novel Approach to Endoscopic Foreign Body Retrieval From the Gastric Body. The American Journal of Gastroenterology, 115(1), s1240-s1240.
Schwarzbaum D, Cohen J, Kim M, Baek S, Ferm S, Shah D, Hussain S & Kim SH (2020) S0601 Risk of Bleeding Following Percutaneous Endoscopic Gastrostomy in Patients on Dual Antiplatelet Therapy. The American Journal of Gastroenterology, 115(1), s300-s300.
Ürün Y, Hussain SA, Bakouny Z, Castellano D, Kılıçkap S, Morgan G, Mckay RR, Pels K, Schmidt A, Doroshow DB , Schütz F et al (2020) Survey of the impact of COVID-19 on oncologists’ decision making in cancer. Jco Global Oncology, 6, 1248-1257.
Al-Jameel W, Gou X, Forootan SS, Fayi MSA, Rudland PS, Forootan FS, Zhang J, Cornford PA, Hussain SA & Ke Y (2020) Correction: Inhibitor SBFI26 suppresses the malignant progression of castration-resistant PC3-M cells by competitively binding to oncogenic FABP5.. Oncotarget, 11(31), 3025-3025.
Pang KH, Thomas F, Novara G, Din OS, Morgan SL, Hussain SA, Jubber I, Noon AP, Catto JWF & Rosario DJ (2020) The Impact of Centralised Services on Metric Reflecting High-quality Performance: Outcomes from 1110 Consecutive Radical Cystectomies at a Single Centre. European Urology Focus.
Fulton B, Jones R, Powles T, Crabb S, Paul J, Birtle A, Chowdhury S, Hussain S, Morris A, Soulis E & Morrison P (2020) ATLANTIS: a randomised multi-arm phase II biomarker-directed umbrella screening trial of maintenance targeted therapy after chemotherapy in patients with advanced or metastatic urothelial cancer. Trials, 21.
Huddart R, Hall E, Lewis R, Porta N, Hussain SA & James ND (2020) Reply to Wei Liu, Xiaoping Liu, Sheng Li’s Letter to the Editor, re: Robert A. Huddart, Emma Hall, Rebecca Lewis, et al. Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial. Eur Urol 2020;77:260–8. European Urology, 77(6), e156-e157.
Hussain SA, Lester JF, Jackson R, Gornall M, Elliott A, Crabb SJ, Huddart RA, Vasudev N, Birtle AJ, Worlding J , James ND et al (2020) Phase II randomized placebo-controlled neoadjuvant trial of nintedanib or placebo with gemcitabine and cisplatin in locally advanced muscle invasive bladder cancer (NEO-BLADE).. Journal of Clinical Oncology, 38(6_suppl), 438-438.
James ND, Pirrie S, Liu W, Ford D, Zarkar A, Southgate E, Desai A & Hussain SA (2020) A phase I/II feasibility study of cetuximab with 5FU and mitomycin C or cisplatin with concurrent radiotherapy in muscle invasive bladder cancer.. Journal of Clinical Oncology, 38(6_suppl), 491-491.
Andrews E, Curran C, Grivas P, Diamantopoulos LN, Drakaki A, Jain RK, Tandon A, Agarwal N, Tripathi A, Santos VS , Hussain SA et al (2020) Outcomes of advanced plasmacytoid urothelial carcinoma receiving systemic therapy.. Journal of Clinical Oncology, 38(6_suppl), 580-580.
Huddart R, Hall E, Lewis R, Porta N, Crundwell M, Jenkins P, Rawlings C, Tremlett J, Campani L, Hendron C , Hussain S et al (2020) Patient reported quality of life outcomes in patients treated for muscle invasive bladder cancer with radiotherapy +/- chemotherapy in the BC2001 phase III randomised controlled trial. European Urology, 77(2), 260-268.
Elmetwali T, Salman A, Wei W, Hussain SA, Young LS & Palmer DH (2020) CD40L membrane retention enhances the immunostimulatory effects of CD40 ligation. Scientific Reports, 10(1). View this article in WRRO
Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain SA, Fléchon A, Bamias A , Yu EY et al (2020) Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. The Lancet Oncology, 21(1), 105-120.
van der Heijden M, Powles T, Petrylak D, de Wit R, Chi K, Necchi A, Sternberg CN, Matsubara N, Nishiyama H, Castellano D , Hussain S et al (2019) Biomarker analyses of ramucirumab in patients with platinum refractory urothelial cancer from RANGE, a global, randomized, double-blind, phase III study. Annals of Oncology, 30, v373-v374.
Pakala T, Cohen J, Bunim A & Hussain S (2019) 2339 Hemobilia-Associated Acute Cholecystitis Post-Percutaneous Liver Biopsy: A Unexpected Sequelae of a Known Complication. The American Journal of Gastroenterology, 114(1), s1304-s1304.
Brodsky T, Rubin M, Karaptis J, Hussain S & Kim S (2019) 545 Converting Inpatient Consults to Directly Scheduled Outpatient Procedures. American Journal of Gastroenterology, 114(1), S315-S315.
Hussain S, Parker S, Edwards K, Finch J, Jeanjean A, Leigh R & Gonem S (2019) Effects of indoor particulate matter exposure on daily asthma control. Annals of Allergy, Asthma & Immunology, 123(4), 375-380.e3.
Elander NO & Hussain SA (2019) Mutation Analysis of the FGFR3-encoding gene Does Not Predict Response to Checkpoint Inhibitor Treatment in Metastatic Bladder Cancer. European Urology, 76(5), 604-606.
Grimm M-O, Bex A, De Santis M, Ljungberg B, Catto JWF, Rouprêt M, Hussain SA, Bellmunt J, Powles T, Wirth M & Van Poppel H (2019) Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019. European Urology, 76(3), 368-380.
Bamias A, Hegele A, Medioni J, Castellano D, Doni L, Passalacqua R, Zagouri F, Tzannia K, Hussain S & Ullen A (2019) Vinflunine in the treatment of relapsed metastatic urothelial cancer: A systematic review and meta-analysis of real-world series. Critical Reviews in Oncology and Hematology. View this article in WRRO
Hussain SA, Maroto P, Climent MÁ, Bianchini D, Jones RH, Lin C-C, Wang S-S, Dean E, Crossley K, Schlieker L , Bogenrieder T et al (2019) Targeting IGF-1/2 with xentuzumab (Xe) plus enzalutamide (En) in metastatic castration-resistant prostate cancer (mCRPC) after progression on docetaxel chemotherapy (DCt) and abiraterone (Abi): Randomized phase II trial results.. Journal of Clinical Oncology, 37(15_suppl), 5030-5030.
Agarwal A, Pond GR, Gupta R, Ornstein MC, Barata PC, Garcia JA, Drakaki A, Lee J-L, Kanesvaran R, Bilen MA , Lorenzo FR et al (2019) First-line PD(L)1 inhibitors for platinum-ineligible advanced urothelial carcinoma (aUC).. Journal of Clinical Oncology, 37(15_suppl), e16024-e16024.
Park SH, Loriot Y, Zhong B, Hussain SA, Mahadevia PJ, De Porre P & Siefker-Radtke AO (2019) Erdafitinib in high-risk patients (pts) with advanced urothelial carcinoma (UC).. Journal of Clinical Oncology, 37(15_suppl), 4543-4543.
Pakala T, Tong M, Ferm S, Hussain S, Kim SH & Rubin M (2019) Mo1645 – The Fecal Occult Blood Test Positive Consult: Inpatient Versus Outpatient Evaluation. Gastroenterology, 156(6), s-814-s-815.
Perez-Gracia JL, Loriot Y, Rosenberg JE, Powles T, Necchi A, Hussain SA, Morales-Barrera R, Retz MM, Niegisch G, Durán I , Théodore C et al (2019) Corrigendum re: “Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens” [Eur Urol 2018;73:462–8]. European Urology, 75(3), e82-e83.
Agarwal A, Pond GR, Drakaki A, Lee J-L, Bilen MA, Di Lorenzo G, Grivas P, Ornstein MC, Barata PC, Gupta S , Hussain SA et al (2019) First-line PD1/PD-L1 inhibitors for platinum-ineligible advanced urothelial carcinoma (UC).. Journal of Clinical Oncology, 37(7_suppl), 432-432.
Slovin S, Hussain S, Saad F, Garcia J, Picus J, Ferraldeschi R, Crespo M, Flohr P, Riisnaes R, Lin C , Keer H et al (2019) Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer. Clinical Cancer Research, 25(15), 4624-4633.
Petrylak DP, Sternberg CN, Drakaki A, de Wit R, Nishiyama H, Necchi A, Castellano D, Bamias A, Chi KN, van der Heijden MS , Matsubara N et al (2018) 865PDRANGE, a phase III, randomized, placebo-controlled, double-blind trial of ramucirumab (RAM) and docetaxel (DOC) in platinum-refractory urothelial carcinoma (UC): Overall survival results. Annals of Oncology, 29(suppl_8), viii304-viii305.
Brodsky T, Ferm S, Hassam A, Siu M, Hussain S, Kim S-H, Gutkin E, Bunim A & Rubin M (2018) Quantification of Hemostatic Clip Usage in Treating Non-Variceal Gastrointestinal Bleeding. The American Journal of Gastroenterology, 113(Supplement), s1553.
Ferm S, Fisher C, Tong M, Rubin M, Hussain S & Kim S-H (2018) Technical and Clinical Outcomes of Colonic Stent Placement in Patients With Proximal Malignant Large Bowel Obstruction. The American Journal of Gastroenterology, 113(Supplement), s96.
Hussain SA, Birtle A, Crabb S, Huddart R, Small D, Summerhayes M, Joners R & Protheroe A (2018) From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma. European Urology Oncology, 1(6), 486-500.
Ferm S, Tong M, Fisher C, Rubin M, Hussain S & Kim SH (2018) Su1710 ENDOSCOPIC MANAGEMENT OF MALIGNANT LARGE BOWEL OBSTRUCTION: A SINGLE-CENTER, COMMUNITY-BASED STUDY. Gastrointestinal Endoscopy, 87(6), ab381.
Ansari J, Farrag AF, Ali A, Ali M, Shaukat AA, Hussein K, Bashir F, Abdel Gelil M, Glaholm J, Hussain SA , Al Hamad A et al (2018) Concurrent nivolumab and radiotherapy to improve outcomes for patients with metastatic lung and renal cancers.. Journal of Clinical Oncology, 36(15_suppl), e15078-e15078.
Pakala T, Kim SH, Hussain S, Chang R & Rubin M (2018) Sa1423 - Tokyo Guidelines Fail to Predict Patients with Severe Purulent Cholangitis. Gastroenterology, 154(6), s-300-s-301.
Perez-Gracia JL, Loriot Y, Rosenberg JE, Powles T, Necchi A, Hussain SA, Morales-Barrera R, Retz MM, Niegisch G, Durán I , Théodore C et al (2018) Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. European Urology, 73(3), 462-468.
Passalacqua R, Medioni J, Castellano DE, Ullén A, Bamias A, Hussain S & Hegele A (2018) Real-world (RW) evidence of vinflunine in metastatic urothelial cancer (mUC): A systematic review of seven European studies.. Journal of Clinical Oncology, 36(6_suppl), 463-463.
Powles T, Durán I, van der Heijden MS, Loriot Y, Vogelzang NJ, De Giorgi U, Oudard S, Retz MM, Castellano D, Bamias A , Fléchon A et al (2018) Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. The Lancet, 391(10122), 748-757.
Ramos JD, Wingate JT, Gulati R, Plimack ER, Harshman LC, Powles T, Crabb SJ, Niegisch G, Bellmunt J, Ladoire S , De Giorgi U et al (2018) Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract Tumors. Clinical Genitourinary Cancer, 16(1), e161-e167.
Necchi A, Pond GR, Smaldone MC, Pal SK, Chan K, Wong Y-N, Viterbo R, Sonpavde G, Harshman LC, Crabb S , Alva A et al (2018) Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist’s Perspective from a Multicentre Study. European Urology Focus, 4(6), 937-945.
Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain S, Fléchon A, Bamias A , Yu EY et al (2017) Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. The Lancet, 390(10109), 2266-2277.
Petrylak DP, Chi KN, Drakaki A, Sternberg CN, de Wit R, Nishiyama H, Yu EY, Castellano D, Hussain S, Percent IJ , Fléchon A et al (2017) LBA4_PR RANGE: A randomized, double-blind, placebo-controlled phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma. Annals of Oncology, 28, v621.
Jones RJ, Hussain SA, Protheroe AS, Birtle A, Chakraborti P, Huddart RA, Jagdev S, Bahl A, Stockdale A, Sundar S , Crabb SJ et al (2017) Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer. Journal of Clinical Oncology, 35(16), 1770-1777.
Lurie LB, Brodsky T, Hussain S, Kim SH & Rubin M (2017) Tu1498 Fully Covered Metal Stents May Be More Effective Than Plastic Stents in Treating Post-Cholecystectomy Bile Leaks. Gastrointestinal Endoscopy, 85(5), ab645.
Carr DF, Ayehunie S, Davies A, Duckworth CA, French S, Hall N, Hussain S, Mellor HR, Norris A, Park BK , Penrose A et al (2017) Towards better models and mechanistic biomarkers for drug-induced gastrointestinal injury. Pharmacology & Therapeutics, 172, 181-194.
Al-Jameel W, Gou X, Forootan SS, Al Fayi MS, Rudland PS, Forootan FS, Zhang J, Cornford PA, Hussain SA & Ke Y (2017) Inhibitor SBFI26 suppresses the malignant progression of castration-resistant PC3-M cells by competitively binding to oncogenic FABP5. OncoTargets and Therapy, 8(19), 31041-31056. View this article in WRRO
Hussain SA, Palmer DH, Syn WK, Sacco JJ, Greensmith RM, Elmetwali T, Aachi V, Lloyd BH, Jithesh PV, Arrand J , Barton D et al (2017) Gene expression profiling in bladder cancer identifies potential therapeutic targets. International journal of oncology, 50(4), 1147-1159.
Hall E, Hussain SA, Porta N, Crundwell M, Jenkins P, Rawlings CL, Tremlett J, Friend C, Stubbs C, Lewis R , James ND et al (2017) BC2001 long-term outcomes: A phase III randomized trial of chemoradiotherapy versus radiotherapy (RT) alone and standard RT versus reduced high-dose volume RT in muscle-invasive bladder cancer.. Journal of Clinical Oncology, 35(6_suppl), 280-280.
Hussain SA, Gomberg S, Probert C, Hickerton B, Jackson R & Weston R (2017) Thrombo-embolic events (TEE) during neoadjuvant chemotherapy for muscle invasive bladder cancer.. Journal of Clinical Oncology, 35(6_suppl), 339-339.
Perez-Gracia JL, Loriot Y, Rosenberg JE, Powles T, Necchi A, Hussain SA, Morales R, Retz M, Niegisch G, Duran I , Theodore C et al (2017) Atezolizumab (atezo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Outcomes by prior therapy.. Journal of Clinical Oncology, 35(6_suppl), 323-323.
Mateo J, Mossop H, Goodall J, Lorente D, Porta N, Carreira S, Miranda S, Zafeiriou Z, Ralph C, Jain S , Jones RJ et al (2017) Association of changes in circulating cell-free plasma DNA (cfDNA) and circulating tumor cells (CTC) during treatment with clinical outcome from olaparib in castration-resistant prostate cancer (CRPC): Exploratory analyses from the TOPARP-A trial.. Journal of Clinical Oncology, 35(6_suppl), 141-141.
Huddart R, Hall E, Miranda M, Crundwell M, Jenkins P, Rawlings C, Tremlett J, Hendron C, Lewis R, Porta N , Hussain S et al (2017) 2115 Quality of life (QL) of muscle invasive bladder cancer (MIBC) patients (pts) receiving radiotherapy (RT) +/- chemotherapy (CT) in the BC2001 trial (CRUK/01/004). European Journal of Cancer, 72, s186-s187.
Choudhury A, West CM, Porta N, Hall E, Denley H, Hendron C, Lewis R, Hussain SA, Huddart R & James N (2017) The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004). British Journal of Cancer, 116(5), 649-657.
Hussain SA, Ansari J, Huddart R, Power DG, Lyons J, Wylie J, Vilarino-Varlela M, Elander NO, McMenemin R, Pickering LM , Faust G et al (2017) VICTOR: Vinflunine in advanced metastatic transitional cell carcinoma of the urothelium: A retrospective analysis of the use of vinflunine in multi-centre real life setting as second line chemotherapy through Free of Charge Programme for patients in the UK and Ireland. International journal of oncology, 50(3), 768-772.
Powles T, Huddart RA, Elliott T, Sarker S-J, Ackerman C, Jones R, Hussain S, Crabb S, Jagdev S, Chester J , Hilman S et al (2017) A phase II/III, double -blind, randomised trial comparing maintenance lapatinib versus placebo after first line chemotherapy in HER1/2 positive metastatic cancer patients.. Journal of Clinical Oncology, 35(1), 48-55.
Al Fayi MS, Gou X, Forootan SS, Al-Jameel W, Bao Z, Rudland PR, Cornford PA, Hussain SA & Ke Y (2016) The increased expression of fatty acid-binding protein 9 in prostate cancer and its prognostic significance. Oncotarget, 7(50), 82783-82797. View this article in WRRO
Bellmunt J, Balar A, Galsky MD, Loriot Y, Theodore C, Grande Pulido E, Castellano D, Retz M, Niegisch G, Bracarda S , Necchi A et al (2016) IMvigor210: updated analyses of first-line (1L) atezolizumab (atezo) in cisplatin (cis)-ineligible locally advanced/metastatic urothelial carcinoma (mUC). Annals of Oncology, 27, vi270-vi270.
Loriot Y, Rosenberg JE, Powles TB, Necchi A, Hussain S, Morales R, Retz M, Niegisch G, Duran I, Theodore C , Perez-Gracia JL et al (2016) 783P Atezolizumab (atezo) in platinum (plat)-treated locally advanced/metastatic urothelial carcinoma (mUC): Updated OS, safety and biomarkers from the Ph II IMvigor210 study. Annals of Oncology, 27, vi270.
Smith M, De Bono J, Sternberg C, Le Moulec S, Oudard S, De Giorgi U, Krainer M, Bergman A, Hoelzer W, De Wit R , Bögemann M et al (2016) Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1. Journal of Clinical Oncology, 34(25), 3005-3013.
Locke JA, Pond GR, Sonpavde G, Necchi A, Giannatempo P, Paluri RK, Niegisch G, Albers P, Buonerba C, Di Lorenzo G , Vaishampayan UN et al (2016) Cisplatin- Versus Non–Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin. Clinical Genitourinary Cancer, 14(4), 331-340.
Andronis L, Goranitis I, Pirrie S, Pope A, Barton D, Collins S, Daunton A, McLaren D, O'Sullivan JM, Parker C , Porfiri E et al (2016) Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747). BJU International. View this article in WRRO
Jones RH, Anthoney DA, Jones RJ, Crabb SJ, Hussain SA, Birtle AJ, Spiliopoulou P, Robinson T, Knowles M, McLellan L , Jones H et al (2016) FIESTA: A phase Ib and pharmacokinetic trial of AZD4547 in combination with gemcitabine and cisplatin.. Journal of Clinical Oncology, 34(15_suppl), 4521-4521.
Latif MF, Tirmazy SH, Hussain SA, Jackson R, Barnett C & Azam F (2016) Management of non metastatic castrate resistant prostate cancer (NM-CRPC), results of a UK wide national survey.. Journal of Clinical Oncology, 34(15_suppl), e16520-e16520.
Elander NO & Hussain SA (2016) PARP Inhibition in Prostate Cancer: A Promising Approach. Oncology, 30(5), 393-394.
James ND, Pirrie SJ, Pope AM, Barton D, Andronis L, Goranitis I, Collins S, Daunton A, McLaren D, O’Sullivan J , Parker C et al (2016) Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both. JAMA Oncology, 2(4), 493-493. View this article in WRRO
Dreicer R, van der Heijden MS, Grivas P, Hoffman-Censits J, Loriot Y, Retz M, Vogelzang NJ, Perez-Gracia JL, Kalebasty AR, Bracarda S , Yu EY et al (2016) PD27-12 PRIMARY ANALYSIS OF IMVIGOR 210: ATEZOLIZUMAB IN PLATINUM-TREATED ADVANCED UROTHELIAL CARCINOMA. Investigative Urology, 195(4), e654.
El-Taji OMS, Alam S & Hussain SA (2016) Bladder Sparing Approaches for Muscle-Invasive Bladder Cancers. Current Treatment Options in Oncology, 17(3).
Powles T, Wheater M, Din O, Geldart T, Boleti E, Stockdale A, Sundar S, Robinson A, Ahmed I, Wimalasingham A , Burke W et al (2016) A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer. European Urology, 69(3), 450-456.
Forootan FS, Forootan SS, Gou X, Yang J, Liu B, Chen D, Fayi MSA, Al-Jameel W, Rudland PS, Hussain SA & Ke Y (2016) Fatty acid activated PPARγ promotes tumorigenicity of prostate cancer cells by up regulating VEGF via PPAR responsive elements of the promoter. Oncotarget, 7(8), 9322-9339.
Powles T, Hussain SA, Protheroe A, Birtle A, Chakraborti PR, Huddart R, Jagdev S, Bahl A, Stockdale A, Sundar S , Crabb SJ et al (2016) PLUTO: A randomised phase II study of pazopanib versus paclitaxel in relapsed urothelial tumours.. Journal of Clinical Oncology, 34(2_suppl), 430-430.
Hussain SA, Khattak AQ, Cornford P, Weston R, Somov P & Jackson R (2016) Outcome of radical cystectomy series in the management of muscle invasive bladder cancer: Liverpool experience.. Journal of Clinical Oncology, 34(2_suppl), 396-396.
Hoffman-Censits JH, Grivas P, Van Der Heijden MS, Dreicer R, Loriot Y, Retz M, Vogelzang NJ, Perez-Gracia JL, Rezazadeh A, Bracarda S , Yu EY et al (2016) IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology, 34(2_suppl), 355-355.
Ramos J, Wong Y-N, Crabb SJ, Niegisch G, Bellmunt J, Ladoire S, Hussain SA, Baniel J, Golshayan AR, Powles T , Rosenberg JE et al (2016) Venous thromboembolism (VTE) risk in patients with localized urinary tract tumors (UTT).. Journal of Clinical Oncology, 34(2_suppl), 422-422.
Nedjadi T, Al-Ammari A, Khayyat D, Salem N, Al-Sayyad A, Hussain SA, Azhar E, Damanhouri G & Al-Maghrabi J (2016) The cell cycle regulator p27^Kip1 is associated with urothelial bladder cancer invasion. International Journal of Clinical and Experimental Pathology, 9(10), 10515-10521.
Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, Nava Rodrigues D, Robinson D, Omlin A, Tunariu N , Boysen G et al (2015) DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. New England Journal of Medicine, 373(18), 1697-1708.
Harshman L, Werner L, Wong YN, Yu E, Alva A, Crabb S, Powles T, Rosenberg J, Baniel J, Vaishampayan U , Berthold D et al (2015) 2619 Patterns and potential benefit of adjuvant chemotherapy for residual muscle invasive disease after neoadjuvant chemotherapy for muscle invasive urothelial cancer (MIUC). European Journal of Cancer, 51, S518-S518.
Hussain S, Jackson R, Chauhan S, Ansari J, Huddart R, Harrold E, Power D, Lyons J, Wylie J, Vilarino-Varela M , Wilkinson D et al (2015) 2632 VICTOR: Vinflunine in advanced metastatic transitional cell carcinoma of the urothelium (TCCU): A retrospective analysis of the use of Vinflunine in a multi-centre real life setting as second line chemotherapy through the free of charge programme (FOCP) for patients in the UK. European Journal of Cancer, 51, s523.
Ananya C, West C, Porta N, Denley H, Hendron C, Hussain S, Hall E, Huddart R & James N (2015) 2642 The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 (CRUK/01/004) trial. European Journal of Cancer, 51, s527-s528.
Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong Y-N, Yu EY, Powles T, Moshier EL, Ladoire S , Hussain SA et al (2015) Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer, 121(15), 2586-2593.
Sundaram V, Hshieh T, Curry M, Kaung A & Hussain S (2015) The international normalized ratio does not reflect bleeding risk in esophageal variceal hemorrhage. Saudi Journal of Gastroenterology, 21(4), 254-254.
EL-TAJI OMS, KHATTAK AQ & HUSSAIN SA (2015) Bladder reconstruction: The past, present and future. Oncology Letters, 10(1), 3-10.
Harshman LC, Werner L, Wong Y-N, Yu EY, Alva AS, Crabb SJ, Powles T, Rosenberg JE, Baniel J, Vaishampayan UN , Berthold DR et al (2015) Adjuvant chemotherapy for residual disease after neoadjuvant chemotherapy for muscle invasive urothelial cancer (MIUC).. Journal of Clinical Oncology, 33(15_suppl), 4524-4524.
Powles T, Huddart RA, Elliott T, Jones R, Hussain SA, Crabb SJ, Ackerman C, Jagdev S, Chester JD, Hilman S , Beresford M et al (2015) A phase II/III, double-blind, randomized trial comparing maintenance lapatinib versus placebo after first line chemotherapy in HER1/2 positive metastatic bladder cancer patients.. Journal of Clinical Oncology, 33(15_suppl), 4505-4505.
Necchi A, Pond GR, Giannatempo P, Di Lorenzo G, Eigl BJ, Locke J, Pal SK, Agarwal N, Poole A, Vaishampayan UN , Niegisch G et al (2015) Cisplatin-Based First-Line Therapy for Advanced Urothelial Carcinoma After Previous Perioperative Cisplatin-Based Therapy. Clinical Genitourinary Cancer, 13(2), 178-184.
Hussain SA, Ansari J, Huddart RA, Wylie J, Vilarino-Varela M, Faust G, Tan M, Lyons J, Hassall A, Escriu C , Chauhan S et al (2015) VICTOR: Vinflunine (Vin) in advanced metastatic transitional cell carcinoma of the urothelium (TCCU)—A retrospective analysis of use of Vin in multicenter, real life setting as second-line chemotherapy (ChT) through free-of charge-programme (FOCP) for patients (pts) in the UK.. Journal of Clinical Oncology, 33(7_suppl), 352-352.
Hussain SA, Jackson R, Shields A, Dickinson L, Cornford P, Jones RJ, Lester JF, Chester J, Birtle AJ, Powles T , Crabb SJ et al (2015) Phase II randomised placebo controlled neoadjuvant chemotherapy study of nintedanib with gemcitabine and cisplatin in locally advanced muscle invasive bladder cancer. Journal of Clinical Oncology, 33 (supplement; abstract TPS4574).
Sharma S, Witteveen PO, Lolkema MP, Hess D, Gelderblom H, Hussain SA, Porro MG, Waldron E, Valera S-Z & Mu S (2015) A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function. Cancer Chemotherapy and Pharmacology, 75(1), 87-95.
Porro M, Sharma S, Witteveen PO, Lolkema MP, Hess D, Gelderblom H, Hussain SA, Waldron E, Valera S & Mu S (2014) 572 Oral panobinostat in patients with advanced tumors and impaired renal function: Relationship between pharmacokinetics and key safety parameters. European Journal of Cancer, 50, 185.
Sonpavde G, Necchi A, Giannatempo P, Di Lorenzo G, Eigl BJ, Locke J, Pal S, Agarwal N, Poole A, Vaishampayan UN , Niegisch G et al (2014) Outcomes with Cisplatin-Based First-Line Therapy for Advanced Urothelial Carcinoma (Uc) Following Previous Perioperative Cisplatin-Based Therapy. Annals of Oncology, 25, iv302.
Ferraldeschi R, Slovin S, Hussain S, Saad F, Garcia J, Kabbinavar FF, Uppal N, Vogelzang NJ, Poiesz BJ, Gelmann E , Picus J et al (2014) A Phase 1/2 Study of At13387, a Heat Shock Protein 90 (Hsp90) Inhibitor in Combination with Abiraterone Acetate (Aa) and Prednisone (P) in Patients (Pts) with Castration-Resistant Prostate Cancer (Mcrpc) No Longer Responding to Aa. Annals of Oncology, 25, iv267.
Hayden A, Douglas J, Sommerlad M, Andrews L, Gould K, Hussain S, Thomas GJ, Packham G & Crabb SJ (2014) The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer. Urologic Oncology: Seminars and Original Investigations, 32(6), 806-814.
Jones RJ, Chester JD, Dixon-Hughes J, Alexander L, Bahl A, Hussain SA, Birtle A, Jagdev S, Morris A, Stobo J , Bray CA et al (2014) Pazopanib versus paclitaxel in relapsed urothelial tumors: A randomized phase II study investigating pazopanib versus weekly paclitaxel in relapsed or progressive transitional cell carcinoma of the urothelium (PLUTO).. Journal of Clinical Oncology, 32(15_suppl), tps4589-tps4589.
Galsky MD, Harshman LC, Crabb SJ, Wong Y-N, Yu EY, Chowdhury S, Powles T, Pal SK, Moshier EL, Ladoire S , Hussain SA et al (2014) Comparative effectiveness of gemcitabine plus cisplatin (GC) versus methotrexate, vinblastine, doxorubicin, plus cisplatin (MVAC) as neoadjuvant therapy for muscle-invasive bladder cancer (MIBC).. Journal of Clinical Oncology, 32(15_suppl), 4512-4512.
Wang WJ, Gray S, Sison C, Arramraju S, John BK, Hussain SA, Kim SH, Mehta P & Rubin M (2014) Low vitamin D level is an independent predictor of poor outcomes in Clostridium difficile-associated diarrhea. Therapeutic Advances in Gastroenterology, 7(1), 14-19.
Johnson PJ, Pirrie SJ, Cox TF, Berhane S, Teng M, Palmer D, Morse J, Hull D, Patman G, Kagebayashi C , Hussain S et al (2014) The Detection of Hepatocellular Carcinoma Using a Prospectively Developed and Validated Model Based on Serological Biomarkers. Cancer Epidemiology Biomarkers & Prevention, 23(1), 144-153.
Huddart RA, Hall E, Hussain SA, Jenkins P, Rawlings C, Tremlett J, Crundwell M, Adab FA, Sheehan D, Syndikus I , Hendron C et al (2013) Randomized Noninferiority Trial of Reduced High-Dose Volume Versus Standard Volume Radiation Therapy for Muscle-Invasive Bladder Cancer: Results of the BC2001 Trial (CRUK/01/004). International Journal of Radiation Oncology*Biology*Physics, 87(2), 261-269.
Bose K, Gutkin E, Kim S, Hussain S, Bunim A & Rubin M (2013) Fecal Immunochemical Testing for Colorectal Cancer Screening in Average Risk Individuals: Fit for Detecting Neoplasia?. The American Journal of Gastroenterology, 108, s628.
Maughan BL, Agarwal N, Hussain SA, Boucher KM, Von Der Maase H, Kaufman DS, Lorusso V, Moore MJ, Galsky MD & Sonpavde G (2013) Pooled Analysis of Phase II Trials Evaluating Weekly or Conventional Cisplatin as First-Line Therapy for Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer, 11(3), 316-320.
Palmer DH, Hussain SA, Smith AJ, Hargreaves S, Ma YT, Hull D, Johnson PJ & Ross PJ (2013) Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom. British Journal of Cancer, 109(4), 888-890.
James ND, Pirrie S, Barton D, Brown JE, Billingham L, Collins SI, Daunton A, Birtle AJ, Chakraborti PR, Ford D , Hussain SA et al (2013) Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747).. Journal of Clinical Oncology, 31(18_suppl), LBA5000-LBA5000.
James ND, Pirrie S, Barton D, Brown JE, Billingham L, Collins SI, Daunton A, Birtle AJ, Chakraborti PR, Ford D , Hussain SA et al (2013) Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial trapeze trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747).. Journal of Clinical Oncology, 31(15_suppl), lba5000-lba5000.
Hussain SA, Palmer DH, Syn WK, Sacco JJ, Lloyd B, Jithesh P, Arrand JR, Barton D, Ansari J, Sibson DR & James ND (2013) Gene expression profiling in bladder cancer to identify potential therapeutic targets.. Journal of Clinical Oncology, 31(15_suppl), 4518-4518.
Gutkin E, Shalomov A, Hussain SA, Kim SH, Cortes R, Gray S, Judeh H, Pollack S & Rubin M (2013) Pillcam ESO® is more accurate than clinical scoring systems in risk stratifying emergency room patients with acute upper gastrointestinal bleeding. Therapeutic Advances in Gastroenterology, 6(3), 193-198.
James ND & Hussain SA (2013) A Multidisciplinary Approach in Muscle-Invasive Disease: Novel Chemotherapy Combinations and Targets in Chemoradiation. American Society of Clinical Oncology Educational Book, 33, 200-206.
Gutkin E, Hussain SA & Kim SH (2012) Changing angles: Successful treatment of superior mesenteric artery syndrome with double-balloon enteroscopy-assisted direct feeding jejunostomy. Digestive Endoscopy, 24(6), 482-482.
NICI AJ, HUSSAIN SA, KIM SH & MEHTA P (2012) UNIQUE USAGE OF A PARTIALLY COVERED METAL STENT FOR DRAINAGE OF A PANCREATIC PSEUDOCYST VIA ENDOSONOGRAPHY-GUIDED TRANSCYSTGASTROSTOMY. Digestive Endoscopy, 24(3), 185-187.
James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, Crundwell M, Sizer B, Sreenivasan T, Hendron C , Lewis R et al (2012) Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer. New England Journal of Medicine, 366(16), 1477-1488.
Nici AJ, Gutkin E, Wang WJ, Kim SH, Hussain SA & Rubin M (2012) Tu1666 Comparison of the Third Eye Retroscope® to Standard Retroflexion in Evaluating the Rectum. Gastrointestinal Endoscopy, 75(4), ab481-ab482.
Gutkin E, Hussain SA, Mehta P, Kim SH, Pollack S & Rubin M (2012) Prevalence of Adenomas Found on Colonoscopy in Patients With HIV.. Gastroenterology Res, 5(2), 52-56.
Gutkin E, Hussain SA & Kim SH (2012) Ketamine-induced Biliary Dilatation. Journal of Addiction Medicine, 6(1), 89-91.
Ansari J, White L, Glen H, McGlynn B, Nairn R, Balsitis M, Hollins G, Smith K, Nair B, Gurun M , Little B et al (2012) Active surveillance for prostate cancer: Scottish experience.. Journal of Clinical Oncology, 30(5_suppl), 167-167.
Agarwal N, Boucher KM, Maughan B, Hussain SA, Kaufman DS, Lorusso V, Moore MJ, Galsky MD & Sonpavde G (2012) Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma (UC).. Journal of Clinical Oncology, 30(5_suppl), 308-308.
Ma YT, Hussain SA, Johnson PJ & Palmer DH (2012) Gemcitabine chemotherapy until symptomatic disease progression in advanced pancreatic cancer: A retrospective analysis.. Journal of Clinical Oncology, 30(4_suppl), 372-372.
Gutkin E, Hussain SA & Kim SH (2012) The Successful Treatment of Chronic Cholecystitis with SpyGlass Cholangioscopy-Assisted Gallbladder Drainage and Irrigation through Self- Expandable Metal Stents. Gut and Liver, 6(1), 136-138.
Bryan RT, Wei W, Shimwell NJ, Collins SI, Hussain SA, Billingham LJ, Murray PG, Deshmukh N, James ND, Wallace DMA , Johnson PJ et al (2011) Assessment of high-throughput high-resolution MALDI-TOF-MS of urinary peptides for the detection of muscle-invasive bladder cancer. PROTEOMICS - Clinical Applications, 5(9-10), 493-503.
Gutkin E, Nici A, Shalomov A, Hussain S, Mehta P, Rubin M & Kim S (2011) Full Liquid Diet vs Clear Liquid Diet for Colonoscopy Preparation: Preliminary Results. The American Journal of Gastroenterology, 106, s559.
Nici A, Hussain S & Kim S (2011) A 14 cm Long Gastro-colic Fistula Repair via a Novel Endoscopic Technique: A Simultaneous Dual Scope Approach Utilizing Endoclips. The American Journal of Gastroenterology, 106, s377.
Gutkin E, Hussain S, Shalomov A, Kim SH, Mehta P, Du L & Rubin M (2011) Diagnosis of multifocal small bowel carcinoid with double balloon Enteroscopy. Practical Gastroenterology, 35(9), 60-63.
Shalomov A, Hussain SA, Kim SH, Palumbo FM & Rubin M (2011) Tu1621 Double Balloon Enteroscopy Assisted Percutaneous Jejunostomy Placement. Gastrointestinal Endoscopy, 73(4), ab465.
Mandair DS, Bridgestock H, Shah T, Mangat K, Olliff S, Mahon B, Hussain S, Johnson P & Palmer D (2011) Effectiveness of trans-arterial embolisation of liver neuroendocrine tumour metastases. Gut, 60(Suppl 1), a115.
Rubin M, Hussain SA, Shalomov A, Cortes RA, Smith MS & Kim SH (2011) Live View Video Capsule Endoscopy Enables Risk Stratification of Patients with Acute Upper GI Bleeding in the Emergency Room: A Pilot Study. Digestive Diseases and Sciences, 56(3), 786-791.
Ansari J, A Hussain S, Alhasso A, Mahmood R, Ansari A & Glaholm J (2011) Role of Second-Line Systemic Treatment Post-Docetaxel in Metastatic Castrate Resistant Prostate Cancer- Current Strategies and Future Directions. Anti-Cancer Agents in Medicinal Chemistry, 11(3), 296-306.
Hussain S, Ma YT & Cullen MH (2011) Tumour biology of germ cell tumours. Hematology/Oncology Clinics of North America, 25, 457-471.
Ma YT, Cullen MH & Hussain SA (2011) Biology of Germ Cell Tumors. Hematology/Oncology Clinics of North America, 25(3), 457-471.
Hassan MSU, Ansari J, Spooner D & Hussain SA (2010) Chemotherapy for breast cancer (review). Oncology Reports, 24(5), 1121-1131.
James N, Hussain S, Hall E, Jenkins P, Tremlett J, Rawlings C, Crundwell M, Waters R & Huddart RA (2010) Results of a 2 x 2 Phase III Randomized Trial of Synchronous Chemo-radiotherapy (CRT) Compared to Radiotherapy (RT) Alone and Standard vs. Reduced High Volume RT in Muscle Invasive Bladder Cancer (MIBC) (BC2001 CRUK/01/004). International Journal of Radiation Oncology • Biology • Physics, 78(3), s2-s3.
Hussain S, Judeh H, Kim S & Mehta P (2010) Endoscopic Ultrasound Guided Drainage of Large Pancreatic Pseudocyst by Partially-Covered Metal Stent. The American Journal of Gastroenterology, 105, s198.
Hussain SA, Palmer DH, Ward DH, Arrand JR, Collins SI, Barton D, Martin A, Porfiri E, Wallace M & James ND (2010) Identification of a molecular profile that may predict early relapse in patients undergoing multimodality therapy in muscle-invasive bladder cancer (MIBC).. Journal of Clinical Oncology, 28(15_suppl), e15118-e15118.
James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, Hendron C, Lewis R, Rogers S & Huddart RA (2010) Results of a phase III randomized trial of synchronous chemoradiotherapy (CRT) compared to radiotherapy (RT) alone in muscle-invasive bladder cancer (MIBC) (BC2001 CRUK/01/004).. Journal of Clinical Oncology, 28(15_suppl), 4517-4517.
Gutkin E, Gray S, Judeh H, Shalomov A, Hussain SA, Cortes RA, Kim SH & Rubin M (2010) S1423: PillCam ESO® Is More Accurate Than Clinical Scoring Systems in Risk Stratifying Emergency Room Patients With Acute Upper Gastrointestinal Bleeding. Gastrointestinal Endoscopy, 71(5), ab157-ab158.
Zeegers MP, Bryan RT, Langford C, Billingham L, Murray P, Deshmukh NS, Hussain S, James N, Wallace DMA & Cheng KK (2010) The West Midlands Bladder Cancer Prognosis Programme: rationale and design. BJU International, 105(6), 784-788.
Ansari J, Glaholm J, McMenemin R, James ND & Hussain SA (2010) Recent Advances and Future Directions in the Management of Metastatic Renal Cell Carcinoma. Anti-Cancer Agents in Medicinal Chemistry, 10(3), 225-235.
(2010) Erratum. Hemodialysis International, 14(1), 152-152.
Hussain S, Ansari J & Spooner D (2010) Advances in chemotherapy in breast cancer.. Oncology Report, 24, 1121-1131.
Hussain SA, Esposito SP & Rubin M (2009) Identification of Small Bowel Diverticula with Double-Balloon Enteroscopy Following Non-diagnostic Capsule Endoscopy. Digestive Diseases and Sciences, 54(10), 2296-2297.
Shalomov A, Hussain S, Cortes R, Kim S, Brodsky N, Somnay K, Smith M & Rubin M (2009) Rapid Evaluation of the Upper GI Tract Using Real-Time Pillcam™ ESO in Emergency Room Patients with Acute UGI Bleeding. The American Journal of Gastroenterology, 104, s502.
Shalomov A, Hussain S, Cortes R, Kim S, Somnay K, Brodsky N, Smith M & Rubin M (2009) Risk Stratification of Upper GI Bleeding Patients in the Emergency Room with “Real Time” Capsule Endoscopy - A Pilot Study. The American Journal of Gastroenterology, 104, s401.
Huddart R, James ND, Adab F, Syndikus I, Jenkins P, Rawlings C, Rogers S, Lewis R, Hendron C, Hussain S & Hall E (2009) 7102 Updated results of the BC2001 phase III randomized trial of standard vs reduced high dose volume radiotherapy for muscle invasive bladder cancer (ISCRTN:68324339): tumour control, toxicity and quality of life. European Journal of Cancer Supplements, 7(2), 423-423.
Hussain SA & Cohen EP (2009) Outcomes of critically ill patients with acute kidney injury and end-stage renal disease requiring renal replacement therapy: a case-control study. Nephrology Dialysis Transplantation, 24(7), 2290-2290.
Ansari J, Palmer D, Rea D & Hussain S (2009) Role of Tyrosine Kinase Inhibitors in Lung Cancer. Anti-Cancer Agents in Medicinal Chemistry, 9(5), 569-575.
Chue AL, Walji N, Rogers LJ, Hussain SA, Chan KK, Singh K & Fernando IN (2009) Adjuvant hysterectomy following unsuccessful intracavitary brachytherapy in cervical carcinoma. Journal of Clinical Oncology, 27(15_suppl), e16543-e16543.
Walji N, Zachariah A, Yap C, Hussain SA, Poole CJ, El-Modir A, Ganesan R & Fernando IN (2009) Carboplatin, ifosfamide, and mesna (CIM) for the treatment of gynecological carcinosarcoma. Journal of Clinical Oncology, 27(15_suppl), e16539-e16539.
HUSSAIN S, PIERING W, MOHYUDDIN T, SALEH M, ZHU Y-R, HANAN M & COHEN E (2009) Outcome among patients with acute renal failure needing continuous renal replacement therapy: A single center study. Hemodialysis International, 13(2), 205-214.
Hussain S, Ansari J, McMenemin R & Glaholm J (2009) Re-challenging with Docetaxel chemotherapy following relapse: Is this an effective treatment strategy. Prostate Cancer Forum, 5, 1-9.
Chue AL, Fernando IN, Hussain SA & Yates DA (2009) Chemotherapy related encephalopathy in a patient with Stage IV cervical carcinoma treated with cisplatin and 5-fluorouracil: a case report. Cases Journal, 2(1), 8526-8526.
Hussain SA, Ma YT, Palmer DH, Hutton P & Cullen MH (2008) Biology of testicular germ cell tumors. Expert Review of Anticancer Therapy, 8(10), 1659-1673.
James ND, Hussain SA, Tremlett J, Crundwell M, Jenkins P, Rawlings C, Hall E, Rogers S & Huddart R (2008) First Toxicity Report of the BC2001 Trial: A Multicentre Phase III Randomised Trial of Radiotherapy with and without Synchronous Chemotherapy in Muscle Invasive Bladder Cancer ISCRTN No. 68324339, EUDRACT No. 2004-000164-26. International Journal of Radiation Oncology • Biology • Physics, 72(1), s7.
Tanguay JS, Buckley L, Hussain SA & Fernando IN (2008) Pegylated liposomal doxorubicin for epithelial ovarian cancer: The utility of Ca125 trends in guiding treatment decisions and subsequent response to platinum retreatment. Journal of Clinical Oncology, 26(15_suppl), 16539-16539.
Ansari J, Hussain SA, Zarkar A, Bliss J, Tanguay JS & Glaholm J (2008) Docetaxel re-treatment for metastatic hormone refractory prostate cancer. Journal of Clinical Oncology, 26(15_suppl), 16066-16066.
John BK, Dang NC, Hussain SA, Yang GCH, Cham MD, Yantiss R, Joseph AS, Giashuddin SM, Lee PC, Fleming R & Somnay K (2008) Multifocal Granular Cell Tumor Presenting as an Esophageal Stricture. Journal of Gastrointestinal Cancer, 39(1-4), 107-113.
Hussain S, Pascoe J, Palmer D, Spooner D & Rea D (2008) Genomics and Pharmacogenomics in the Management of Breast Cancer. Current Pharmacogenomics and Personalized Medicine, 6(1), 45-55.
Hussain SA, Ting Ma Y & Cullen MH (2008) Management of metastatic germ cell tumors. Expert Review of Anticancer Therapy, 8(5), 771-784.
Gill JS, Hussain S, Rose C, Hariharan S & Tonelli M (2007) Access to Kidney Transplantation among Patients Insured by the United States Department of Veterans Affairs. Journal of the American Society of Nephrology, 18(9), 2592-2599.
Hussain SA, Ward D, Palmer DH, Barton D, Veeranna V, Porfiri E, Martin A, Wallace M & James ND (2007) The role of neoadjuvant chemotherapy in muscle invasive bladder cancer and correlation of clinical outcome with translational studies. Journal of Clinical Oncology, 25(18_suppl), 15551-15551.
Hussain SA, Rea DW & Palmer DH (2007) Reply: Randomised studies with translational end points are required to further elucidate the prognostic and predictive value of CA IX. British Journal of Cancer, 96(8), 1310-1310.
Hussain SA, Ganesan R, Reynolds G, Gross L, Stevens A, Pastorek J, Murray PG, Perunovic B, Anwar MS, Billingham L , James ND et al (2007) Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer. British Journal of Cancer, 96(1), 104-109.
Hussain SA, Palmer DH, Spooner D & Rea DW (2007) Molecularly Targeted Therapeutics for Breast Cancer. BioDrugs, 21(4), 215-224.
Hussain S, Rea D, James N & Palmer D (2007) Signal Transduction Therapy: Challenges to Clinical Trial Design. Current Signal Transduction Therapy, 2(1), 21-30.
Basu PP, Palumbo FM, Maltby M, Hussain S, Somnay K & Mendis RE (2006) Rifaximin, Omeprazole and Levofloxacin for the Treatment of Helicobacter pylori in the Treatment-Naive Population. The American Journal of Gastroenterology, 101, s90-s91.
Hussain SA & Hariharan S (2006) BK virus infection after renal transplantation. Current Opinion in Organ Transplantation, 11(4), 413-417.
Saad ER, Bresnahan B, Cohen EP, Hussain S, Vasudev B, Orentas R & Hariharan S (2006) REDUCTION IN IMMUNOSUPPRESSION WITHOUT USE OF ANTI-VIRAL THERAPY IN THE TREATMENT OF BK VIRUS INFECTION AFTER RENAL TRANSPLANT.. Transplantation, 82(1), 938-939.
Hussain SA, Palmer DH, Swinson DE, Riley P, Brown C, Wills A, El-Modir A, Rea DW, Chetiyawardana AD & Cullen MH (2006) A feasibility/phase II study of gemcitabine (G) and split dose cisplatin (C) in advanced or metastatic non-small cell lung cancer (NSCLC) in an outpatient setting. Journal of Clinical Oncology, 24(18_suppl), 17048-17048.
Vasudev B, Hariharan S, Hussain SA, Zhu Y-R, Bresnahan BA & Cohen EP (2005) BK virus nephritis: Risk factors, timing, and outcome in renal transplant recipients. Kidney International, 68(4), 1834-1839.
Hussain SA, Palmer DH, Swinson DE, Bailey C, Billingham L, Riley P, El-Modir A, Rea DW, Chetiyawardana AD & Cullen MH (2005) A pilot/phase II study of gemcitabine (G) and split dose cisplatin (C) in advanced or metastatic non-small cell lung cancer (NSCLC) in an outpatient setting. Journal of Clinical Oncology, 23(16_suppl), 7272-7272.
Hussain S, Savin V, Piering W, Tomasi J & Blumenthal S (2005) Phosphorus-enriched hemodialysis during pregnancy: Two case reports. Hemodialysis International, 9(2), 147-152.
JAMES N & HUSSAIN S (2005) Management of muscle invasive bladder cancer?British approaches to organ conservation. Seminars in Radiation Oncology, 15(1), 19-27.
Palmer DH, Hussain SA & Johnson PJ (2005) Gene- and immunotherapy for hepatocellular carcinoma. Expert Opinion on Biological Therapy, 5(4), 507-523.
Hussain SA, Palmer DH, Stevens A, Spooner D, Poole CJ & Rea DW (2005) Role of chemotherapy in breast cancer. Expert Review of Anticancer Therapy, 5(6), 1095-1110.
HUSSAIN S & JAMES N (2005) Molecular markers in bladder cancer. Seminars in Radiation Oncology, 15(1), 3-9.
Bryan RT, Hussain SA, James ND, Jankowski JA & Wallace DMA (2005) Molecular pathways in bladder cancer: Part 1. BJU International, 95(4), 485-490.
Bryan RT, Hussain SA, James ND, Jankowski JA & Wallace DMA (2005) Molecular pathways in bladder cancer: Part 2. BJU International, 95(4), 491-496.
Hussain S & James ND (2005) Management of muscle invasive bladder cancer – can we improve the results of bladder preserving therapy?. Seminars in Radiation Oncology, 15(1), 19-27.
Palmer DH, Hussain SA & Johnson PJ (2004) Systemic therapies for hepatocellular carcinoma. Expert Opinion on Investigational Drugs, 13(12), 1555-1568.
Hussain SA, Stocken DD, Riley P, Palmer DH, Peake DR, Geh JI, Spooner D & James ND (2004) A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer. British Journal of Cancer, 91(5), 844-849.
Hussain SA, Stocken DD, Peake DR, Glaholm JG, Zarkar A, Wallace DMA & James ND (2004) Long-term results of a phase II study of synchronous chemo radiotherapy in muscle invasive bladder cancer. Journal of Clinical Oncology, 22(14_suppl), 4585-4585.
Hussain SA, Stocken DD, Peake DR, Glaholm JG, Zarkar A, Wallace DMA & James ND (2004) Long-term results of a phase II study of synchronous chemo radiotherapy in muscle invasive bladder cancer. Journal of Clinical Oncology, 22(14_suppl), 4585-4585.
Hussain SA, Stocken DD, Peake DR, Glaholm JG, Zarkar A, Wallace DMA & James ND (2004) Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer. British Journal of Cancer, 90(11), 2106-2111.
Hussain SA, Williams S, Stevens A & Rea DW (2004) Endocrine therapy for early breast cancer. Expert Review of Anticancer Therapy, 4(5), 877-888.
Hussain SA, Palmer DH, Moon S & Rea DW (2004) Endocrine therapy and other targeted therapies for metastatic breast cancer. Expert Review of Anticancer Therapy, 4(6), 1179-1195.
Hussain S, Ganesan R, Palmer DH, Cooke PW, Wallace DM, Young LS & James ND (2004) CD40 expression in prostatic carcinomas. Oncology Reports: an international journal devoted to fundamental and applied research in oncology, 12(4), 679-682.
Hussain S, Palmer DH, Ganesan R, Hillier L, Gregory J, Pastorek J, Murray P, Young LS & James ND (2004) Role of hypoxic marker CA IX in Transitional cell carcinoma of the bladder.. Oncology Reports: an international journal devoted to fundamental and applied research in oncology, 11(5), 1005-1010.
Hussain S, Williams S, Stevens A & Rea DW (2004) Role of endocrine therapy in early breast cancer. Expert Review of Anticancer Therapy, 5, 877-888.
Hussain S, Palmer DH, Moon S & Rea DW (2004) Role of endocrine therapy in metastatic breast cancer.. Expert Review of Anticancer Therapy, 6, 1179-1195.
Hussain SA & James ND (2003) The systemic treatment of advanced and metastatic bladder cancer. The Lancet Oncology, 4(8), 489-497.
McCabe CJ, Khaira JS, Boelaert K, Heaney AP, Tannahill LA, Hussain S, Mitchell R, Olliff J, Sheppard MC, Franklyn JA & Gittoes NJL (2003) Expression of pituitary tumour transforming gene (PTTG) and fibroblast growth factor-2 (FGF-2) in human pituitary adenomas: relationships to clinical tumour behaviour. Clinical Endocrinology, 58(2), 141-150.
Hussain SA, Ganesan R, Hiller L, Murray PG, El-Magraby MM, Young L & James ND (2003) Proapoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladder. British Journal of Cancer, 88(4), 586-592.
Cohen EP, Hussain S & Moulder JE (2003) Successful treatment of radiation nephropathy with angiotensin II blockade. International Journal of Radiation Oncology*Biology*Physics, 55(1), 190-193.
Hussain SA, Ganesan R, Hiller L, Cooke PW, Murray P, Young LS & James ND (2003) BCL2 expression predicts survival in patients receiving synchronous chemoradiotherapy in advanced transitional cell carcinoma of the bladder. Oncology Reports, 10(3), 571-576.
Hussain SA & James ND (2002) Organ preservation strategies in bladder cancer. Expert Review of Anticancer Therapy, 2(6), 641-651.
McCabe CJ, Boelaert K, Tannahill LA, Heaney AP, Stratford AL, Khaira JS, Hussain S, Sheppard MC, Franklyn JA & Gittoes NJL (2002) Vascular Endothelial Growth Factor, Its Receptor KDR/Flk-1, and Pituitary Tumor Transforming Gene in Pituitary Tumors. The Journal of Clinical Endocrinology & Metabolism, 87(9), 4238-4244.
Hussain S, Bresnahan BA, Cohen EP & Hariharan S (2002) Rapid kidney allograft failure in patients with polyoma virus nephritis with prior treatment with antilymphocyte agents. Clinical Transplantation, 16(1), 43-47.
Hussain SA, Moffitt DD, Glaholm JG, Peake D, Wallace DMA & James ND (2001) A phase I–II study of synchronous chemoradiotherapy for poor prognosis locally advanced bladder cancer. Annals of Oncology, 12(7), 929-935.
Mulholland PJ, Ferry DR, Anderson D, Hussain SA, Young AM, Cook JE, Hodgkin E, Seymour LW & Kerr DJ (2001) Pre-clinical and clinical study of QC12, a water-soluble, pro-drug of quercetin. Annals of Oncology, 12(2), 245-248.
Chung-Faye G, Palmer D, Anderson D, Clark J, Dowries M, Baddeley J, Hussain S, Murray PI, Searle P, Seymour L , Ferry D et al (2001) Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: A phase I and pharmacokinetic study of its prodrug, CB1954. Clinical Cancer Research, 7(9), 2662-2668.
Hussain SA, Ferry DR, El-Gazzaz G, Mirza DF, James ND, McMaster P & Kerr DJ (2001) Hepatocellular carcinoma. Annals of Oncology, 12(2), 161-172.
Hussain SA & James N (2000) Role of chemotherapy in anal tumours. GI Cancer, 3(3), 181-187.
Ansari (1994) Docetaxel chemotherapy for metastatic hormone refractory prostate cancer as first-line palliative chemotherapy and subsequent re-treatment: Birmingham experience. Oncology Reports, 20(4).
Wheatley DA, Berardi R, Climent Duran MA, Tomiak A, Greystoke AP, Joshua AM, Arkenau H-T, Géczi L, Garcia-Corbacho J, Paz-Ares LG , Hussain SA et al () First-line avelumab plus chemotherapy in patients with advanced solid tumors: results from the phase 1b/2 JAVELIN Chemotherapy Medley study. Cancer Research Communications.
Jones RJ, Crabb SJ, Linch M, Birtle AJ, McGrane J, Enting D, Stevenson R, Liu K, Kularatne B & Hussain SA () Systemic anticancer therapy for urothelial carcinoma: UK oncologists’ perspective. British Journal of Cancer.
Macaulay VM, Lord S, Hussain S, Maroto JP, Jones RH, Climent MÁ, Cook N, Lin C-C, Wang S-S, Bianchini D , Bailey M et al () A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer. British Journal of Cancer.
Jubber I, Morhardt DR, Griffin J, Cumberbatch M, Glover M, Zheng Y, Rehman I, Loynes C, Hussain SA, Renshaw SA , Leach SD et al () Analysis of the distal urinary tract in larval and adult zebrafish reveals homology to the human system. Disease Models & Mechanisms.
Riaz IB, Naqvi SAA, He H, Asghar N, Siddiqi R, Liu H, Singh P, Childs DS, Ravi P, Hussain SA , Murad MH et al () First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer. JAMA Oncology.
Riaz IB, Islam M, Ikram W, Naqvi SAA, Maqsood H, Saleem Y, Riaz A, Ravi P, Wang Z, Hussain SA , Warner JL et al () Disparities in the Inclusion of Racial and Ethnic Minority Groups and Older Adults in Prostate Cancer Clinical Trials. JAMA Oncology.
James ND, Liu W, Pirrie S, Kaur B, Hendron C, Ford D, Zarkar A, Viney R, Southgate E, Desai A & Hussain SA () TUXEDO: A phase I/II trial of cetuximab with chemoradiotherapy in muscle‐invasive bladder cancer. BJU International.
Jubber I, Mitchell S, Hussain S, Tsoi H, Catto JWF & Cumberbatch MG () Social deprivation and bladder cancer: cause or effect for disparities in survival for affected women. BJU International.
Gordon NS, Baxter LA, Goel A, Arnold R, Kaur B, Liu W, Pirrie SJ, Hussain S, Viney R, Ford D , Zarkar A et al () Urine dna for monitoring chemoradiotherapy response in muscle‐invasive bladder cancer: A pilot study. BJU International.
Bin Riaz I, Khan AM, Catto JWF & Hussain SA () Bladder cancer: shedding light on the most promising investigational drugs in clinical trials. Expert Opinion on Investigational Drugs.
Crabb SJ, Danson S, Catto JWF, Hussain S, Chan D, Dunkley D, Downs N, Marwood E, Day L, Saunders G , Light M et al () Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE). Clinical Cancer Research.
Al-Hujaily E, Khatlani T, Alehaideb Z, Ali R, Almuzaini B, Alrfaei B, Iqbal J, Islam I, Malik S, Marwani B , Massadeh S et al () Therapeutics discovery: From bench to first in-human trials*. Biomedical Reports.
Nici A, Hussain S, Rubin M & Kim S () Repair of a gastrocolic fistula using a wire-guided, simultaneous dual scope approach. Endoscopy, 45(S 02), E307-E308.
Palmer D, Hussain S, Ganesan R, Cooke P, Wallace D, Young L & James N () CD40 expression in prostate cancer: A potential diagnostic and therapeutic molecule. Oncology Reports.
Hussain S, Palmer D, Ganesan R, Hiller L, Gregory J, Murray P, Pastorek J, Young L & James N () Carbonic anhydrase IX, a marker of hypoxia: Correlation with clinical outcome in transitional cell carcinoma of the bladder. Oncology Reports.
() Molecular Mechanisms Involved in the Transition of Prostate Cancer Cells from Androgen Dependant to Castration Resistant State. Journal of Andrology and Gynaecology, 2(3).
Ansari J, Hussain , Glaholm & Ansari A () Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma. Biologics: Targets and Therapy, 39-39. View this article in WRRO
Simmons J, Hussain S, Riley P & Wallace DM () Management of renal angiomyolipoma in patients with tuberous sclerosis complex. Oncology Reports.
Hussain S () A study of split-dose cisplatin-based neo-adjuvant chemotherapy in muscle-invasive bladder cancer. Oncology Letters.
Hussain S, Palmer D, Swinson D, Riley P, Wills A, Brown C, Draycott C, El-Modir A, Peake D, Rea D , Chetiyawardana A et al () A phase II clinical trial of gemcitabine and split dose cisplatin in advanced non-small cell lung cancer in an outpatient setting. Oncology Reports.
Okorie M, Hussain S, Riley P & McCafferty I () The use of self-expandable metal stents in the palliation of malignant bowel obstruction. Oncology Reports.
Choudhury A, Porta N, Hall E, Song YP, Owen R, MacKay R, West C, Lewis R, Hussain S, James N , Huddart R et al () Hypofractionated radiotherapy in invasive bladder cancer: an individual patient data meta‐analysis of the BC2001 and BCON trials. Lancet Oncology.

Chapters

Hussain S & James ND (2013) A multidisciplinary approach in muscle-invasive disease In Hussain S (Ed.), American Society Clinical Oncology Education Book
Hussain S & Palmer DH (2013) Systematic chemotherapy for liver tumours In Fong , Poon , Tang , Dupuy & Berlin (Ed.), Hepatobiliary Cancer
Hussain S, James ND, Bryan R, Patel P & Viney R (2012) Bladder cancer, in Perez and Brady's Principles and Practice of Radiation Oncology In Halperin EC, Wazer DE, Perez CA & Brady LW (Ed.), Percy and Brady textbook of radiation oncology
Hussain S, Zarkar A & James N (2008) Concomitant chemo-radiotherapy principles and management In Price (Ed.), Treatment of Cancer

Conference proceedings papers

Naqvi SAA, Saxena A, Faisal KS, Bibi A, Khan MA, Cobran EK, Hussain SA, Bin Riaz I, Bryce AH & Singh P (2024) Stratified absolute benefit with adjuvant immunotherapy (aIO) in muscle-invasive bladder cancer (MIBC): A meta-analysis. JOURNAL OF CLINICAL ONCOLOGY, Vol. 42(16)
Naqvi SAA, Faisal KS, Raina A, Khakwani KZR, Bin Riaz Z, Shah VS, Cobran EK, Singh P, Hussain SA, Bryce AH & Bin Riaz I (2024) Cost-effectiveness analysis of contemporary first-line (1L) agents in locally advanced/metastatic urothelial carcinoma (la/mUC). JOURNAL OF CLINICAL ONCOLOGY, Vol. 42(16)
Crabb SJ, Hussain SA, Oughton JB, Swain J, Cairns DA, Collinson M, Ainsworth G, McCready D, Griffin J, Heath P , Quayle L et al (2024) Use of gene expression patterns to identify unique molecular subtypes in muscle invasive bladder cancer: GUSTO. JOURNAL OF CLINICAL ONCOLOGY, Vol. 42(16)
Necchi A, Hussain SA, Loriot Y & de Velasco G (2024) SOGUG-NEOWIN: A Phase 2, open-label, multi-centre, multi-national interventional trial evaluating the efficacy and safety of Erdafitinib (ERDA) monotherapy and ERDA and Cetrelimab (CET) as neoadjuvant treatment in cisplatin-ineligible patients with Muscle-Invasive Bladder Cancer (MIBC) whose tumours express FGFR gene alterations. EUROPEAN UROLOGY, Vol. 85 (pp S427-S427)
Naqvi SAA, Bin Riaz I, He H, Imran M, Orme J, Childs DS, Ravi P, Hussain SA, Singh P & Bryce AH (2023) The role of volume of disease for treatment selection in patients with metastatic castration sensitive prostate cancer (mCSPC): A living meta-analysis. JOURNAL OF CLINICAL ONCOLOGY, Vol. 41(16)
Khetrapal P, Catto J, Ambler G, Williams N, Al-Hammouri T, Khan MS, Thurairaja R, Nair R, Nathan S, Sridhar A , Ahmad I et al (2023) MEASURING OBJECTIVE RECOVERY OF ACTIVITY LEVELS USING WEARABLE DEVICES FOLLOWING OPEN VS INTRACORPOREAL ROBOTIC CYSTECTOMY: SECONDARY OUTCOMES ANALYSIS OF THE IROC RANDOMIZED TRIAL. JOURNAL OF UROLOGY, Vol. 209 (pp E985-E985)
Ikram W, Naqvi SAA, Raina A, Fatima E, Siddiqi R, Islam M, Asghar N, Khakwani KZR, Khan AM, Hussain SA , Bryce AH et al (2022) Quantifying the absolute benefit of neoadjuvant chemotherapy followed by definitive therapy in patients with muscle-invasive bladder cancer: A systematic review and meta-analysis.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 40(16)
Riaz IB, Naqvi SAA, He H, Asghar N, Siddiqi R, Khakwani KZR, Liu H, Hussain SA, Singh P, Murad M & Bryce AH (2022) Mixed treatment comparisons evaluating contemporary therapies in metastatic castration sensitive prostate cancer (mCSPC): A living systematic review. ANNALS OF ONCOLOGY, Vol. 33(7) (pp S1193-S1193)
Jones RJ, Hussain SA, Birtle AJ, Song YP, Enting D, Faust G, Hilman S, Jagdev S, McGovern UB, Parikh O , Lewis A et al (2022) A randomised, double blind, phase II clinical trial of maintenance cabozantinib following chemotherapy for metastatic urothelial carcinoma (mUC): Final analysis of the ATLANTIS cabozantinib comparison.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 40(17)
Khetrapal P, Catto J, Ambler G, Ricciardi F, Khan S, Feber A, Dixon S, Williams N, Ahmed I, Charlesworth P , Cumberbatch M et al (2022) RESULTS OF THE INTRACORPOREAL ROBOTIC VS OPEN CYSTECTOMY (IROC) MULTI-CENTRE RANDOMISED TRIAL. JOURNAL OF UROLOGY, Vol. 207(5) (pp E695-E695)
Hussain SA, Lester JF, Jackson R, Gornall M, Elliott A, Crabb SJ, Huddart RA, Vasudev N, Birtle AJ, Worlding J , James ND et al (2020) Phase II randomized placebo-controlled neoadjuvant trial of nintedanib or placebo with gemcitabine and cisplatin in locally advanced muscle invasive bladder cancer (NEO-BLADE). JOURNAL OF CLINICAL ONCOLOGY, Vol. 38(6)
Andrews E, Curran C, Grivas P, Diamantopoulos LN, Drakaki A, Jain RK, Tandon A, Agarwal N, Tripathi A, Santos VS , Hussain SA et al (2020) Outcomes of advanced plasmacytoid urothelial carcinoma receiving systemic therapy. JOURNAL OF CLINICAL ONCOLOGY, Vol. 38(6)
James ND, Pirrie S, Liu W, Ford D, Zarkar A, Southgate E, Desai A & Hussain SA (2020) A phase I/II feasibility study of cetuximab with 5FU and mitomycin C or cisplatin with concurrent radiotherapy in muscle invasive bladder cancer. JOURNAL OF CLINICAL ONCOLOGY, Vol. 38(6)
Hussain SA (2019) Changing Landscape in the Management of Advanced Bladder Cancer. JOURNAL OF PATHOLOGY, Vol. 249 (pp S10-S10)
Porta N, Song YP, Hall E, Choudhury A, Owen R, Lewis R, Hussain S, James ND, Huddart RA & Hoskin P (2019) Hypo-Fractionation in Muscle-Invasive Bladder Cancer: An Individual Patient Data (IPD) Meta-Analysis of the BC2001 and BCON Trials. International Journal of Radiation Oncology*Biology*Physics, Vol. 105(1) (pp S138-S138)
Van der Heijden M, Powles T, Petrylak D, de Wit R, Chi K, Necchi A, Sternberg CN, Matsubara N, Nishiyama H, Castellano D , Hussain S et al (2019) Biomarker analyses of ramucirumab in patients with platinum refractory urothelial cancer from RANGE, a global, randomized, double-blind, phase III study. ANNALS OF ONCOLOGY, Vol. 30
Jani VB, Patel A, Schurr J, Shell E, Bey J, Mitchell M, Shippey R, Kassab M, Razak A, Safdar A , Majid A et al (2016) Difference in Acute Ischemic Post Thrombolytic Stroke Outcomes in Pre Comprehensive and Post Comprehensive Status: Single Center Experience. STROKE, Vol. 47
Powles T, Wheater MJ, Din O, Geldart TR, Boleti E, Stockdale A, Sundar S, Robinson A, Ahmed I, Sarker S-J , Hussain SA et al (2015) A randomized phase II study of AZ2014 versus everolimus in patients with VEGF refractory metastatic clear cell renal cancer (mRCC).. Journal of Clinical Oncology, Vol. 33(7_suppl) (pp 409-409)
James ND, Pirrie S, Barton D, Brown JE, Billingham L, Collins SI, Daunton A, Birtle AJ, Chakraborti PR, Ford D , Hussain SA et al (2013) Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747).. JOURNAL OF CLINICAL ONCOLOGY, Vol. 31(18)
James ND, Pirrie S, Barton D, Brown JE, Billingham L, Collins SI, Daunton A, Birtle AJ, Chakraborti PR, Ford D , Hussain SA et al (2013) Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial trapeze trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747).. JOURNAL OF CLINICAL ONCOLOGY, Vol. 31(15)

Posters

Khetrapal P, Catto J, Ambler G, Ricciardi F, Khan S, Feber A, Dixon S, Williams N, Ahmed I, Charlesworth P , Cumberbatch M et al (2022) PD42-02 RESULTS OF THE INTRACORPOREAL ROBOTIC VS OPEN CYSTECTOMY (IROC) MULTI-CENTRE RANDOMISED TRIAL.

Preprints

Jubber I, Morhardt DR, Griffin J, Cumberbatch M, Glover M, Zheng Y, Rehman I, Loynes C, Hussain SA, Renshaw SA , Leach SD et al (2023) Analysis of the Distal Urinary Tract in Larval and Adult Zebrafish Reveals Unrecognized Homology to the Human System, Cold Spring Harbor Laboratory.
Fulton B, Jones R, Powles T, Crabb S, Paul J, Birtle A, Chowdhury S, Hussain S, Morris A, Soulis E & Morrison P () ATLANTIS: An adaptive multi-arm phase II trial of maintenance targeted therapy after chemotherapy in patients with metastatic urothelial cancer, Research Square Platform LLC.
Fulton B, Jones R, Powles T, Crabb S, Paul J, Birtle A, Chowdhury S, Hussain S, Morris A, Soulis E & Morrison P () ATLANTIS: An adaptive multi-arm phase II trial of maintenance targeted therapy after chemotherapy in patients with metastatic urothelial cancer, Research Square Platform LLC.

Teaching interests

I regularly taught pharmacology to both undergraduate and postgraduate students in my previous roles and supervised both MSc and PhD students in both their projects and research. I am also:

Deputy Lead of Urology & Renal Phase 2a MBChB
Academic Lead for Medical Oncology Clinical Academic Training Programme.

Professional activities and memberships

Association of Cancer Physicians (ACP)
European Society of Medical Oncology (ESMO)
American Society of Clinical Oncology (ASCO)
NCRI Blader & Renal Clinical studies group
British Medical Association
Chair of the NCRI Advanced Bladder Cancer – subgroup